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Antibacterial activityAbstract 4-Acyl-pyrazole-3-carboxylic acids (1) were synthesized via the reaction of 4-acyl-2,3-
furandiones (F) with hydrazone (1-benzylidene-2-(2,5-dimethyl-phenyl)-hydrazine) by heating
under solid phase and their acid chlorides (2) were obtained. Then these derivatives were easily con-
verted into the corresponding derivatives such as ester, amide, ureide, pyrazolo-pyridazine, etc.
Totally 62 new compounds were synthesized. The structures of these new synthesized compounds
were determined by spectroscopic methods and the in vitro antibacterial activity of newly synthe-
sized compounds were carried out against some gram-positive and gram-negative bacteria by well
diffusion method (zone inhibition). Our results have showed that these new synthesized compounds
have much potent of antibacterial activity owing to containing of pyrazole and/or pyridazine, chro-
mone, oxazine, furane, and pyrrole rings. Some of the new pyrazole derivatives exhibited higher
activities than reference drugs against the representative bacteria.
 2016 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Natural antibiotic compounds used in the treatment and pre-
vention of bacterial infection have become necessary for the
current health care system, assisting and complementing the
natural immune system against microbial pathogens. How-
ever, because conventional antibiotics are often abused/over-used to treat microbial infections, some microorganisms have
developed resistance to some of these antibiotics [1]. So the
medical communities are faced in a serious problem with
antimicrobial and antibiotic resistance, so much as to prompt
the World Health Organization (WHO) to classify antimicro-
bial resistance as a ‘‘serious threat that is no longer a predic-
tion for the future, it is happening right now in every region
of the world and has the potential to affect anyone, of any
age, in any country” (‘‘WHO’s first global report on antibiotic
resistance reveals serious, worldwide threat to public health”
The World Health Organization, April 30, 2014. Retrieved
December 21, 2014.). These bacterial strains that are resistant
to conventional antibacterial therapies have prompted the
development of novel efficient antibiotic agents that are alter-
natives to conventional antibacterial therapies [2,3].y (2016),
2 A. C¸etin, _I. BildiriciOn the other hand, the pyrazole ring that contains a five-
membered heterocyclic organic compound with two adjacent
nitrogen atoms is a prominent heterocyclic scaffold in lots of
bioactive molecules. They are important substances and have
gained widespread attention in agrochemical, pharmaceutical
and chemical industries [4]. They possess a wide range of bio-
logical activities [5–8], including antimicrobial [9–16], antiviral
[17–20], anticancer [21,22], antiinflammatory [23–26], antihis-
taminic [27], pesticidal [28], antifungal [29–31], against
rheumatoid arthritis [32], anticonvulsant [33], antidepressant
[34], antipyretic [35,36], antibacterial [37,38] agents, etc. and
these bio-activities have inspired chemists to synthesize substi-
tuted pyrazole systems to explore the usefulness of this hetero-
cyclic template. In recent years, a number of pyrazole-
containing compounds have been successfully commercialized
such as the blockbuster drugs Viagra (Sildenafil inhibits phos-
phodiesterase) [39], Celebrex [40] (Celecoxib demonstrates
antiinflammation effect and inhibits COX-2), Rimonabant
(trade name Acomplia) functions as cannabinoid receptor
and is utilized in obesity treatment, Fomepizole (It is on the
World Health Organization’s List of Essential Medicines) inhi-
bits alcohol dehydrogenase, Ceftolozane (Zerbaxa) is a 5th
generation cephalosporin antibiotic (Food and Drug Adminis-
tration approved on 2014), Pyrazomycin (Pyrazofurin) antivi-
ral agents, hormone oxytocin agonists (WAY-VNA-932).
Moreover, some pyrazole-containing compounds are used
as a-Helix mimetic [41] and applied as ligands for the
transition-metal-catalyzed cross-coupling reactions [42,43]
(Fig. 1).
As a matter of fact, pyrazole derivatives have been studied
for a long time as an important class of heterocyclic com-
pounds and still continue to attract considerable attention
according to all this information. Hence, these ones are popu-
lar targets for synthetic chemists. Classic methods for the syn-
thesis of pyrazoles involve the approaches based either on the
condensation of hydrazines with 1,3-dicarbonyl compounds
[44,45] and their 1,3-dielectrophilic equivalents including a,b-
unsaturated aldehydes and ketones [46] or on the intermolecu-
lar 1,3-dipolar cycloaddition of diazoalkanes and nitrilimines
with alkenes and alkynes [47,48]. A simple and effective
procedure in the preparation of pyrazole derivatives is the
nucleophilic addition of hydrazines to 4-acyl-5-phenyl-2,3-
furandiones F [49] in various solvent or solventless [50–53].
In addition, heterocyclic scaffolds such as pyridazine, chro-
mone, oxazine, furane and pyrrole derivatives have various
and valuable biological activities such as antimicrobial, anti-
cancer, anti-HIV and antimalarial properties [54–58].N
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pyrazole containing aforementioned active pharmacophores
in order to incorporate them in a novel single molecule.
Besides, we aimed to report (1) synthesis, (2) characterization
of unknown analogs of 4-acyl-pyrazole derivatives and (3)
antibacterial activities of newly synthesized 4-acyl-pyrazoles
against representative gram-negative and gram-positive bacte-
ria. Hence, this work might be a precious original mini review
for pyrazole chemistry particularly for 4-acyl-pyrazole deriva-
tives and their bioactivities.
2. Experimental
2.1. Materials and methods
All reagents and solvents were of reagent grade quality and
were obtained from commercial suppliers. All solvents were
dried by refluxing with appropriate drying agents and distilled
before use. Follow up of the reactions and checking the purity
of the compounds was made and tested in each step by TLC
(SiO2) using a DC Alufolien Kieselgel 60 F 254 Merck. Com-
pounds were visualized by Camag TLC devices UV
(254/366 nm). Melting points were determined on an Elec-
trothermal Gallenkamp apparatus and are uncorrected. Ele-
mental analyses were performed on Thermo Scientific Flash
2000. The FT-IR spectra were obtained as potassium bromide
pellets using a Mattson 1000 FTIR spectrometer. The 1H and
13C NMR spectra were recorded on Bruker Instrument
Avance Series-Spectrospin DPX-400 Ultra Shield, using
TMS as an internal standard. Chemical shifts are given in d,
ppm. Splitting patterns were designated as follows: s: singlet;
d: doublet; t: triplet; q: quartet; m: multiplet; and br: broad.
The mass spectrum was measured on Agilent LC/MSD
spectrometers.
2.2. Synthesis of compounds
2.2.1. 4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-pyrazole-
3-carboxylic acid (1a)
An equimolar mixture of furandione F (0.278 g, 1 mmole)
and 1-benzylidine-2-(2,5-dimethylphenyl)hydrazine (0.224 g,
1 mmole) were reacted in solid phase for approximately
40 min. The oily residue obtained was treated with dry ether.
The crude product formed was crystallized from an ethyl alco-
hol to give 0.38 g (75%) of 1a, mp 202 C; IR (m, cm1): 3271
(OAH, COOH), 3040 (aromatic CAH), 2921 (aliph. CAH),SO
O
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(400 MHz, DMSO-d6) d (ppm): 13.10 (br, 1H, AOH), 7.77–
6.96 (m, 13H, ArAH), 2.23 (s, 3H, ArACH3),
13C NMR
(100 MHz, DMSO-d6) d (ppm): 191.42 (C‚O, benzoyl),
162.75 (C‚O, COOH), 144.48 (C3), 143.67 (C5), 142.33,
141.31, 138.91, 138.32, 138.04, 133.14, 130.73, 130.57, 129.70,
129.46, 129.30, 129.06, 128.78, 127.68, 127.89, 109.21 (C4),
18.85, 14.19 (ACH3). Anal. Cal. for C26H20N2O3
(396,44 g/mol): C, 75.74; H, 5.08; N, 7.07. Found: C, 75.67;
H, 5.11; N, 7.15.
2.2.2. 1-(2,5-Dimethylphenyl)-4-(ethoxycarbonyl)-5-phenyl-
1H-pyrazole-3-carboxylic acid (1b)
An equimolar mixture of furandione F (0.246 g, 1 mmole)
and 1-benzylidine-2-(2,5-dimethylphenyl)hydrazine (0.224 g,
1 mmole) were reacted solid phase for approximately 40 min.
The oily residue obtained was treated with dry ether. The
crude product formed was crystallized from a toluene to give
0.31 g (65%) of 1b, mp 202 C, IR (m, cm1): 3246 (OAH,
COOH), 3066 (aromatic CAH), 2918 (aliph. CAH), 1732
(C‚O, ester), 1710 (C‚O, COOH), 1H NMR (400 MHz,
CDCl3) d (ppm): 9.88 (br, 1H, AOH), 7.97–6.81 (m, 8H,
ArAH), 4.18 (q, 2H, ACH2), 2.19, 1.85 (s, 3H, ArACH3),
1.31 (t, 3H, ACH3),
13C NMR (100 MHz, CDCl3) d (ppm):
168.16 (C‚O, ester), 166.09 (C‚O, COOH), 145.59 (C3),
144.37 (C5), 143.60, 136.39, 135.49, 133.32, 132.10, 130.85,
129.73, 129.62, 129.30, 128.92, 128.45, 127.24, 114.19 (C4),
60.73 (OACH2), 21.50, 17.50 (ArACH3), 14.30 (-CH3). Anal.
Cal. for C21H20N2O4 (364,39 g/mol): C, 69.22; H, 5.53; N,
7.69. Found: C, 69.15; H, 5.50; N, 7.74.
2.2.3. 4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-pyrazole-
3-carbonyl chloride (2a)
Compound 1a (0.397 g, 1 mmole) was refluxed with excessive
SOCl2 at 80 C for about 7 h. Excessive SOCl2 was evaporated.
Remaining oily product was purified in dry ether/cyclohexane
mixture, which was crystallized from n-hexane/cyclohexane, to
yield 0.31 g (60%); mp 145 C; IR (m, cm1): 3045 (aromatic
CAH), 2920 (aliph. CAH), 1720 (C‚O, acyl), 1664 (C‚O,
benzoyl), 1H NMR (400 MHz, CDCl3) d (ppm): 8.08–6.42
(m, 13H, ArAH), 2.09, 1.75 (s, 3H, ArACH3),
13C NMR
(100 MHz, CDCl3) d (ppm): 193.12 (PhAC‚O), 167.77
(ACOCl), 143.46 (C3), 137.33 (C5), 135.96, 135.33, 133.33,
132.47, 132.24, 131.70, 130.41, 129.99, 129.74, 129.38, 128.81,
128.70, 128.25, 127.43, 126.88, 121.50 (C4), 22.99, 14.05
(ArACH3). Anal. Cal. for C25H19ClN2O2 (414,88 g/mol): C,
72.37; H, 4.62; N, 6.75. Found: C, 72.29; H, 4.61; N, 6.83.
2.2.4. Ethyl 3-(cholorocarbonyl)-1-(2,5-dimethylphenyl)-5-
phenyl-1H-pyrazole-4-carboxylate (2b)
Compound 1b (0.397 g, 1 mmole) was refluxed with excessive
SOCl2 at 80 C for about 7 h. Excessive SOCl2 was evaporated.
Remaining oily product was purified in dry ether which was
crystallized from toluene, to yield 0.31 g (65%), mp 118 C;
IR (m, cm1): 3090 (aromatic CAH), 2924 (aliph. CAH),
1723 (C‚O, acyl), 1659 (C‚O, ester), 1H NMR (400 MHz,
CDCl3) d (ppm): 7.64–6.54 (m, 8H, ArAH), 4.22 (q, 2H,
ACH2), 2.28, 1.73 (s, 3H, ArACH3), 1.42 (t, 3H, ACH3),
13C
NMR (100 MHz, CDCl3) d (ppm): 167.34 (C‚O, acyl),
164.50 (C‚O, ester), 145.16 (C3), 144.32 (C5), 143.56,
136.79, 135.92, 134.14, 132.35, 131.44, 130.36, 129.70, 129.31,Please cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
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19.15 (ArACH3), 15.70 (ACH3). Anal. Cal. for C21H19ClN2O3
(382,84 g/mol): C, 65.88; H, 5.00; N, 7.32. Found: C, 65.78; H,
5.02; N, 7.41.
2.2.5. General procedure for synthesis of ester
Compound 3a–b can be synthesized in two different methods.
Method A: To the cold solution of the pyrazole acid 1a
(0.397 g, 1 mmole) in sulfuric acid was added a large excess
of methanol with stirring. Then the reaction mixture was
refluxed on a steam bath for 4 h with stirring. After cooling
the precipitate formed was filtered off and crystallized from
the same alcohol to give 3a–b.
Method B: The acid chloride 2a (0.414 g, 1 mmole) and a
moderate excess of the methyl alcohol were refluxed together
with a catalytic amount of pyridine for 3 h. After cooling,
the solution was acidified by adding diluted hydrochloric acid
(12%) to give a crude solid that was crystallized from methyl
alcohol.
2.2.5.1. Methyl 4-benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carboxylate (3a). The yield was 0.35 g (85%), mp
180 C; IR (m, cm1): 3100 (aromatic CAH), 2951 (aliph.
CAH), 1723 (C‚O, ester), 1663 (C‚O, benzoyl), 1H NMR
(400 MHz, CDCl3) d (ppm): 7.87–6.46 (m, 13H, ArAH), 3.75
(s, 3H, AOCH3), 2.11, 1.75 (s, 3H, ArACH3),
13C NMR
(100 MHz, CDCl3) d (ppm): 191.39 (C‚O, benzoyl), 161.77
(C‚O, ester), 144.81 (C3), 143.29 (C5), 142.06, 138.11,
136.29, 135.31, 133.30, 132.34, 129.96, 129.31, 128.57, 128.50,
128.25, 127.55, 126.82, 122.01, 107.15 (C4), 52.18 (ACH3),
18.91, 17.33 (ArACH3). Anal. Cal. for C26H22N2O3
(410,46 g/mol): C, 76.08; H, 5.40; N, 6.82. Found: C, 75.97;
H, 5.37; N, 6.91.
2.2.5.2. Ethyl 4-benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carboxylate (3b). Compound 3b was obtained in
70% yield (0.31 g) by method A and B. IR (m, cm1): 3100
(aromatic CAH), 2924 (aliph. CAH), 1718 (C‚O, ester),
1666 (C‚O, benzoyl), 1H NMR (400 MHz, CDCl3) d
(ppm): 7.89–6.93 (m, 13H, ArAH), 4.19 (q, 2H, -OCH2), 2.2,
1.7 (s, 3H, ArACH3), 1.07 (t, 3H, ACH3),
13C NMR
(100 MHz, CDCl3) d (ppm): 191.44 (C‚O, benzoyl), 161.29
(C‚O, ester), 144.81 (C3), 143.29 (C5), 142.35, 140.51,
139.42, 138.51, 135.61, 133.29, 132.34, 131.35, 130.04, 129.37,
128.56, 128.51, 128.24, 127.63, 126.81, 121.71 (C4), 61.35
(OACH2), 18.93, 17.37 (ArACH3), 13.80 (ACH3). Anal. Cal.
for C27H24N2O3 (424,49 g/mol): C, 76.39; H, 5.70; N, 6.60.
Found: C, 76.32; H, 5.73; N, 6.65.
2.2.6. 4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-pyrazole-
3-carboxamide (3c)
A moderate stream of gaseous ammonia was allowed to bub-
ble through a solution of pyrazole-3-carboxylic acid chloride
2a (0.414 g, 1 mmole) in 20 mL hexane during 30 min with
ice-cooling. Then the crude precipitate was isolated by filtra-
tion and crystallized from methanol to give 0.29 g (70%) of
3c, mp 293 C; IR (m, cm1): 3434 (ANH2), 3080 (aromatic
CAH), 2910 (aliph. CAH), 1693 (C‚O, benzoyl), 1664
(C‚O, amide), 1H NMR (400 MHz, CDCl3) d (ppm): 7.89–
6.93 (m, 8H, ArAH), 5.46 (b, 2H, ANH2), 2.14, 1.82 (s, 3H,
ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 192.90icrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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(C5), 137.91, 137.46, 136.24, 133.33, 131.76, 130.78, 129.60,
129.54, 129.41, 129.25, 129.10, 128.32, 128.13, 127.70, 120.95
(C4), 20.74, 17.12 (ArACH3). Anal. Cal. for C25H21N3O2
(395,45 g/mol): C, 75.93; H, 5.35; N, 10.63. Found: C, 75.84;
H, 5.37; N, 10.69.
2.2.7. 4-Benzoyl-1-(2,5-dimethylphenyl)-N,5-diphenyl-1H-
pyrazole-3-carboxamide (3d)
An equimolar mixture of the acid chloride 2a (0.414 g,
1 mmole) and n-phenyl amine (1 mmole) was refluxed in xylene
for 4 h. After evaporation, the oily residue was treated with
dry ether and the formed crude product was crystallized from
ether/chloroform. The yield 0.3 g (60%), mp 205 C; IR
(m, cm1): 3224 (-NH), 3040 (aroma. CAH), 2910 (aliph.
CAH), 1693 (C‚O, benzoyl), 1664 (C‚O, amide), 1H
NMR (400 MHz, CDCl3) d (ppm): 9.02 (b, 1H, NH), 7.88–
6.73 (m, 13H, ArAH), 2.18, 1.75 (s, 3H, ArACH3),
13C
NMR (100 MHz, CDCl3) d (ppm): 191.56 (C‚O, benzoyl),
163.61 (C‚O, amide), 145.60 (C3), 142.18 (C5), 137.63,
136.66, 133.70, 133.64, 132.36, 131.93, 131.39, 129.60, 129.56,
129.40, 129.38, 129.25, 129.29, 128.56, 128.20, 127.60, 126.12,
122.21 (C4), 21.70, 17.37 (ArACH3). Anal. Cal. for
C31H25N3O2 (471,55 g/mol): C, 78.96; H, 5.34; N, 8.91. Found:
C, 78.85; H, 5.32; N, 8.91.
2.2.8. 4-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carboxamido)- benzene-sulfonic acid (3e)
A miliequimolar mixture of compound 2a and 4-
aminobenzenesulfonic acid were refluxed in toluene for 6 h.
After the solvent was removed by evaporation, the oily residue
was treated with ether and the crude product formed was crys-
tallized from methanol. The yield was 0.23 g (40%), mp
222 C; IR (m, cm1): 3100 (aromatic CAH), 2922 (aliph.
CAH), 1669 (C‚O, benzoyl), 1H NMR (400 MHz, CDCl3)
d (ppm): 10.02 (s, 1H, ANH), 8.82–6.88 (m, 17H, ArAH),
2.36 (b, 1H, AOH), 2.2, 1.85 (s, 3H, ArACH3).
13C NMR
(100 MHz, CDCl3) d (ppm): 191.76 (C‚O, benzoyl), 162.79
(C‚O, amide), 143.68 (C3), 141.57 (C5), 143.36, 133.27,
132.70, 131.86, 130.86, 130.51, 130.16, 129.80, 129.40, 129.30,
128.93, 128.37, 128.20, 125.96, 125.32, 124.48 (C4), 21.54,
17.37 (ArACH3). Anal. Cal. for C31H25N3O5S
(551,61 g/mol): C, 67.50; H, 4.57; N, 7.62. Found: C, 67.41;
H, 4.60; N, 7.68.
2.2.9. 4-2-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonyl)-hydrazinyl- benzene-sulfonic acid (3f)
Compound 3f was prepared according to the synthesis of 3e.
The yield was 0.36 g (60%), mp 243 C; IR (m, cm1): 3131–
3144 (ANH), 3000 (aromatic CAH), 2984 (aliph. CAH),
1669 (C‚O, benzoyl), 1669 (HNAC‚O), 1H NMR
(400 MHz, CDCl3) d (ppm): 10.08 (b, 2H, ANH), 7.89–6.58
(m, 17H, ArAH), 5.65 (d, 2H, ANH), 2.2, 1.85 (s, 3H,
ArACH3), 1.90 (b, 1H, AOH),
13C NMR (100 MHz, CDCl3)
d (ppm): 192.62 (C‚O, benzoyl), 164.13 (C‚O, amide),
146.13 (C3), 144.32 (C5), 141.12, 139.57, 136.41, 134.55,
133.67, 133.36, 132.65, 132.53, 131.77, 131.02, 130.79, 130.63,
130.21, 129.84, 129.46, 129.04, 128.73, 128.54, 128.02, 127.45,
127.20, 121.40, 121.23 (C4), 20.74, 16.89 (ArACH3), MS (m/
z): Calc.=566.1, Found = 566.1.Please cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
http://dx.doi.org/10.1016/j.jscs.2016.05.0082.2.10. 1-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonyl)-urea (3g)
The yield 0.37 g (80%), mp 199 C; IR (m, cm1): 3421 (b,
ANH), 3072 (aromatic CAH), 2846 (aliph. CAH), 1703
(C‚O, benzoyl), 1664 (C‚O, urea), 1H NMR (400 MHz,
CDCl3) d (ppm): 9.01 (b, 1H, ANH), 7.83–6.44 (m, 13H,
ArAH), 5.64 (s, 2H, ANH2), 2.14, 1.76 (s, 3H, ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 194.43 (C‚O, ben-
zoyl), 162.89 (C‚O, amide), 160.47 (C‚O, urea), 145.46
(C3), 144.69 (C5), 143.28, 142.42, 140.88, 138.14, 137.46,
136.31, 135.49, 133.61, 132.20, 131.60, 129.67, 129.56, 128.58,
128.17, 127.73, 127.04, 126.01, 120.72 (C4), 19.02, 17.34
(ArACH3). Anal. Cal. for C26H22N4O3 (438,48 g/mol): C,
71.22; H, 5.06; N, 12.78. Found: C, 71.16; H, 5.04; N, 12.84.
2.2.11. 1-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonyl)-3-methylurea (3h)
(0.33 g, 70%), mp 185 C; IR (m, cm1): 3335–3121 (b, ANH),
3059 (aromatic CAH), 2865 (aliph. CAH), 1668 (C‚O, ben-
zoyl), 1668 (C‚O, urea), 1H NMR (400 MHz, CDCl3) d
(ppm): 9.05 (b, 1H, ANH), 7.83–6.44 (m, 13H, ArAH), 6.31
(q, 1H, ANH), 2.54 (d, 3H, CH3), 2.02, 1.76 (s, 3H, ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 191.08 (C‚O, ben-
zoyl), 161.55 (C‚O, amide), 160.00 (C‚O, urea), 145.95
(C3), 142.08 (C5), 141.13, 137.62, 136.97, 133.64, 131.71,
131.12, 131.00, 129.84, 129.60, 129.51, 129.40, 128.60, 128.15,
127.11, 125.31, 121.78 (C4), 37.60 (N-CH3), 19.02, 17.34
(ArACH3). Anal. Cal. for C27H24N4O3 (452,50 g/mol): C,
71.67; H, 5.35; N, 12.38. Found: C, 71.59; H, 5.37; N, 12.45.
2.2.12. 1-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonyl)-3-phenylurea (3i)
(0.38 g, 70%); mp 200 C; IR (m, cm1): 3389–3154 (b, ANH),
3060 (aromatic CAH), 2925 (aliph. CAH), 1670 (C‚O, ben-
zoyl), 1670 (C‚O, urea), 13C NMR (100 MHz, CDCl3) d
(ppm): 191.64 (C‚O, benzoyl), 166.92 (C‚O, amide),
165.14 (C‚O, urea), 145.71 (C3), 144.30 (C5), 138.23,
135.49, 133.44, 132.12, 131.69, 131.29, 130.93, 129.82, 129.37,
129.25, 129.04, 128.68, 128.18, 127.74, 114.21 (C4), 19.74,
17.11 (ArACH3). Anal. Cal. for C32H26N4O3 (514,57 g/mol):
C, 74.69; H, 5.09; N, 10.89. Found: C, 74.60; H, 5.10; N, 10.93.
2.2.13. 4-benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonyl isothiocyanate (3j)
Compound 5 of 0.199 g (0.5 mmole) was dissolved in 20 mL
anhydrous acetone and to a solution of 0.38 g, 0.5 mmole
ammonium thiocyanate in dry acetone added the reaction
pot. The reaction mixture refluxed four hour in a round-
bottom flask equipped with condenser and the solvent was
evaporated and residue compound was washed with ether and
the formed precipitated product was filtered and the crude pro-
duct was from n-hexane/ether by crystallization. (0,18 g, 60%),
mp 159 C; IR (m, cm1): 3053–3023 (aromatic CAH), 2957
(aliph. CAH), 1698 (C‚O, benzoyl), 1670 (C‚O), 1H NMR
(400 MHz, CDCl3) d (ppm): 7.78–6.97 (m, 13H, ArAH), 2.09,
1.27 (s, 3H, ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm):
190.24 (C‚O, benzoyl), 183.01 (C‚O), 147.13 (N‚C‚S),
143.63 (C3), 141.59 (C5), 138.03, 137.89, 136.44, 135.80,
134.66, 133.23, 131.14, 131.08, 129.18, 126.11, 114.89, 109.19
(C4), 19.77, 17.96 (ArACH3). Anal. Cal. for C26H19N3O2Sicrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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4.40; N, 9.65.
2.2.14. 1-(4-benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonyl)thiourea (3k)
Compound 3k can be synthesized in two different methods.
Method A: Compound 2a of 0.404 g, 1 mmole and 0,038 g,
1 mmole thiourea was refluxed in xylene for 5 h. After evapo-
ration, the oily residue was treated with dry ether, the formed
precipitated product was filtered and the crude product was
crystallized from ethanol (0.05 g, 21%).
Method B: Compound 3j of 0.219 g, 0,5 mmole was dis-
solved in 10 mL anhydrous acetone and drop wise addition
of ammonia was heated at reflux temperature for 4 h. After
heating to room temperature, stirring was continued 1 h after-
ward poured into 10 mL cold water, the formed precipitated
product was filtered and the crude product was crystallized
from ethanol. (0,085 g, 38%), mp 192 C; IR (m, cm1): 3204
(b, ANH), 3057 (aromatic CAH), 2924 (aliph. CAH), 1661
(C‚O, benzoyl), 1634 (C‚S, thioamide), 1H NMR
(400 MHz, DMSO) d (ppm): 8.19 (b, 1H, ANH), 7.92–6.55
(m, 13H, ArAH), 2.08, 1.09 (s, 3H, ArACH3), 1.61 (s, 2H,
ANH2),
13C NMR (100 MHz, DMSO) d (ppm): 189.53
(C‚O, benzoyl), 178.61, (C‚S, thioamide), 163.72 (C‚O,
amide), 142.73 (C3), 141.69 (C5), 141.36, 137.28, 136.53,
135.63, 134.78, 133.42, 131.23, 131.15, 128.35, 125.92, 113.62
(C4), 20.24, 17.85 (ArACH3). Anal. Cal. for C26H22N4O2S
(454,54 g/mol): C, 68.70; H, 4.88; N, 12.33. Found: C, 68.61;
H, 4.87; N, 12.39.
2.2.15. 1-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonyl)-3-ethylthiourea (3l)
Compound 3l was prepared according to method B. (0.16 g,
44%), mp 201 C; (was crystallized from propyl alcohol); IR
(m, cm1): 3196 (ANH), 3049 (aromatic CAH), 2853 (aliph.
CAH), 1700 (C‚O, benzoyl), 1680 cm1 (C‚O, amide),
1666 (C‚S, thioamide), 1H NMR (400 MHz, DMSO) d
(ppm): 8.3 (b, 1H, ANH), 7.92–6.72 (m, 13H, ArAH), 4.1 (q,
2H, CH2), 2.10, 1.75 (s, 3H, ArACH3), 1.1 (t, 3H, CH3),
13C
NMR (100 MHz, DMSO) d (ppm): 204.29 (C‚O, benzoyl),
181.14 (C‚S, thioamide), 162.54 (C‚O, amide), 143.52
(C3), 141.62 (C5), 138.13, 136.18, 135.49, 132.72, 131.50,
130.53, 129.21, 127.19, 125.23, 121.63, 108.13 (C4), 59.03
(-CH2), 22.01, 16.92 (ArACH3), 12.35 (CH3). Anal. Cal. for
C28H26N4O2S (482,60 g/mol): C, 69.69; H, 5.43; N, 11.61.
Found: C, 69.58; H, 5.44; N, 11.72.
2.2.16. 4-Ethyl 3-methyl 1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3,4-dicarboxylate (3m)
Compound 3m was prepared according to the general proce-
dure for synthesis of ester. (0.32 g, 80%), mp 150 C; (was
crystallized from methanol); IR (m, cm1): 3064 (aromatic
CAH), 2980 (aliph. CAH), 1723 (C‚O, ester) 1H NMR
(400 MHz, CDCl3) d (ppm): 7.9–6.8 (m, 8H, ArAH), 4.2 (q,
2H, ACH2), 3.7 (s, 3H, AOCH3) 2.0, 1.7 (s, 3H, ArACH3),
1.1 (t, 3H, ACH3),
13C NMR (100 MHz, CDCl3) d (ppm):
163.16 (C‚O, ester), 161.48 (C‚O, ester), 143.35 (C3),
141.30 (C5), 138.12, 135.24, 134.56, 131.97, 130.46, 130.05,
129.19, 126.60, 110.33 (C4), 60.12 (ACH2), 35.28 (AOCH3)
23.56, 17.21 (ArACH3), 13.02 (ACH3). Anal. Cal. forPlease cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
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C, 69.72; H, 5.88; N, 7.51.
2.2.17. Diethyl 1-(2,5-dimethylphenyl)-5-phenyl-1H-pyrazole-
3,4-dicarboxylate (3n)
Compound 3n was prepared according to the general proce-
dure for synthesis of ester. (0.25 g, 60%), mp 165 C; (was
crystallized from ethanol); IR (m, cm1): 3026 (aromatic
CAH), 2979 (aliph. CAH), 1721 (C‚O, ester), 1H NMR
(400 MHz, CDCl3) d (ppm): 7.55–6.38 (m, 8H, ArAH), 4.35
(q, 4H, ACH2), 2.18, 1.78 (s, 3H, ArACH3), 1.36 (t, 3H,
ACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 161.14,
160.83 (C‚O, ester), 143.71 (C3), 141.64 (C5), 139.25,
135.47, 134.59, 131.88, 130.63, 129.36, 122.20, 110.33 (C4),
55.47, 48.91 (OACH2), 21.35, 17.29 (ArACH3), 15.34, 13.60
(ACH3). Anal. Cal. for C23H24N2O4 (392,45 g/mol): C,
70.39; H, 6.16; N, 7.14. Found: C, 70.33; H, 6.12; N, 7.22.
2.2.18. Ethyl 3-carbamoyl-1-(2,5-dimethylphenyl)-5-phenyl-
1H-pyrazole-4-carboxylate (3o)
Compound 3o was prepared according to the general proce-
dure for synthesis of amide. (0.32 g, 80%); mp 263 C; (was
crystallized from ethanol); IR (m, cm1): 3221 (ANH2), 3021
(aromatic CAH), 2969 (aliph. CAH), 1735 (C‚O, ester),
1725(C‚O, amide), 1H NMR (400 MHz, CDCl3) d (ppm):
7.77–7.07 (m, 8H, ArAH), 4.19 (q, 2H, CH2), 2.10, 1.76 (s,
3H, ArACH3), 1.22 (t, ACH3),
13C NMR (100 MHz, CDCl3)
d (ppm): 171.32 (C‚O, ester), 166.01 (C‚O, amide), 144.42
(C3), 143.35 (C5), 138.26, 134.63, 132.12, 131.49, 130.78,
130.04, 129.85, 129.22, 128.52, 127.78, 125.62, 110.25 (C4),
61.35 (ACH2), 21.46, 19.03 (ArACH3), 14.15 (ACH3). Anal.
Cal. for C22H24N3O3 (378,44 g/mol): C, 69.82; H, 6.39; N,
11.10. Found: C, 69.71; H, 6.40; N, 11.19.
2.2.19. Ethyl 1-(2,5-dimethylphenyl)-3-(ethylcarbamoyl)-5-
phenyl-1H-pyrazole-4-carboxylate (3p)
Compound 3pwas prepared according to the general procedure
for synthesis of amide. (0.23 g, 55%), mp 155 C; (was crystal-
lized from ethanol); IR (m, cm1): 3385 (ANH), 3010 (aromatic
CAH), 2825 (aliph. CAH), 1715 (C‚O, ester), 1616 (C‚O,
amide), 1H NMR (400 MHz, CDCl3) d (ppm): 9.12 (b, 1H,
NH), 7.70–6.59 (m, 8H, ArAH), 4.25 (q, 2H, CH2), 2.01,1.75
(s, 3H, ArACH3), 1,21 (t, 3H, CH3),
13C NMR (100 MHz,
CDCl3) d (ppm): 171.38 (C‚O, ester), 168.41 (C‚O, amide),
144.39 (C3), 142.51 (C5), 140.86, 135.99, 132.32, 131.29,
130.01, 129.80, 129.68, 129.14 128.52, 127.77, 126.82, 110.25
(C4), 61.35 (OACH2), 35.11 (CH2ANH), 21.46, 19.03
(ArACH3), 16.51, 14.68 (ACH3). Anal. Cal. for C23H25N3O3
(391,46 g/mol): C, 70.57; H, 6.44; N, 10.73. Found: C, 70.48;
H, 6.45; N, 10.80.
2.2.20. Ethyl 1-(2,5-dimethylphenyl)-5-phenyl-3-
(phenylcarbamoyl)-1H-pyrazole-4-carboxylate (3r)
Compound 3r was prepared according to the general proce-
dure for synthesis of amide. (0.24 g, 50%), mp 205 C; (was
crystallized from isoamylalcohol/secondary butyl alcohol);
IR (m, cm1): 3219 (ANH), 3045 (aromatic CAH), 2923 (aliph.
CAH), 1732 (C‚O, ester), 1633 (C‚O, amide), 13C NMR
(100 MHz, CDCl3) d (ppm): 165.41 (C‚O, ester), 162.56
(C‚O, amide), 145.34 (C3), 144.14 (C5), 136.14, 135.63,icrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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128.58, 128.26, 127.43, 114.30 (C4), 50.31 (OACH2), 20.48,
17.35 (ArACH3), 12.10 (ACH3). Anal. Cal. for C27H25N3O3
(439,51 g/mol): C, 73.78; H, 8.78; N, 9.56. Found: C, 73.67;
H, 8.75; N, 10.09.
2.2.21. Ethyl 1-(2,5-dimethylphenyl)-5-phenyl-3-
(ureidocarbonyl)-1H-pyrazole-4-carboxylate (3s)
Compound 3s was prepared according to the general proce-
dure for synthesis of urea. (0.33 g, 75%); mp 228 C, (was crys-
tallized from isoamylalcohol); IR (m, cm1): 3408–3157 (b,
NAH), 3054 (aromatic CAH), 2923 (aliph. CAH), 1732
(C‚O, ester), 1690 (C‚O, urea), 1H NMR (400 MHz,
CDCl3) d (ppm): 8.76 (b, 1H, ANH), 7.78–6.90 (m, 8H,
ArAH), 5.54 (s, 2H, ANH2), 4.20 (q, 3H, CH2), 1.95, 1.69
(s, 3H, ArACH3), 1.29 (t, 3H, CH3),
13C NMR (100 MHz,
CDCl3) d (ppm): 166.19 (C‚O, ester), 162.03 (C‚O, amide),
158.54 (C‚O, urea), 143.66 (C3), 142.27 (C5), 140.35, 135.57,
134.20, 130.79, 130.38, 129.54, 122.41, 107.54 (C4), 51.80
(ACH2), 22.48, 17.25 (ArACH3), 14.66 (CH3). Anal. Cal. for
C22H22N4O4 (406,43 g/mol): C, 65.01; H, 5.46; N, 13.78.
Found: C, 64.87; H, 5.49; N, 13.87.
2.2.22. Ethyl 1-(2,5-dimethylphenyl)-3-((3-methylureido)-
carbonyl)-5-phenyl-1H-pyrazole-4-carboxylate (3t)
Compound 3t was prepared according to the general proce-
dure for synthesis of urea. (0.32 g, 70%); mp 262 C, (was crys-
tallized from secondary butyl alcohol); IR (m, cm1): 3401–
3157 (b, NAH), 3014 (aromatic CAH), 2916 (aliph. CAH),
1702 (C‚O, ester), 1700 (C‚O, urea), 1H NMR (400 MHz,
CDCl3) d (ppm): 8.08 (b, 1H, ANH), 7.37–6.56 (m, 8H,
ArAH), 5.44 (s, 1H, ANH), 4.19 (q, 2H, CH2), 3.49 (t, 3H,
CH3), 2.06, 1.78 (s, 3H, ArACH3), 1,18 (t, 3H, CH3),
13C
NMR (100 MHz, CDCl3) d (ppm): 168.55 (C‚O, ester),
166.72 (C‚O, amide), 161.49 (C‚O, urea), 145.27 (C3),
143.64 (C5), 141.12, 136.13, 132.29, 131.44, 130.57, 130.23,
129.67, 128.36, 125.37, 106.10 (C4), 58.82 (OACH2), 31.19
(CH3ANH), 24.28, 18.10 (ArACH3), 15.36 (CH3). Anal. Cal.
for C23H24N4O4 (420,46 g/mol): C, 65.70; H, 5.75; N, 13.33.
Found: C, 65.59; H, 5.77; N, 13.41.
2.2.23. Ethyl 1-(2,5-dimethylphenyl)-3-((3-ethylureido)-
carbonyl)-5-phenyl-1H-pyrazole-4 carboxylate (3u)
Compound 3u was prepared according to the general proce-
dure for synthesis of urea. (0.24 g, 50%), mp 220 C; (was crys-
tallized from chloroform/n-hexane); IR (m, cm1): 3367–3100
(b, NAH), 3055 (aromatic CAH), 2928 (aliph. CAH), 1722
(C‚O, ester), 1722 (C‚O, urea), 1H NMR (400 MHz,
CDCl3) d (ppm): 8.45 (b, 1H, ANH), 7.70–6.79 (m, 8H,
ArAH), 5.39 (s, 1H, ANH), 4.58 (q, 2H, CH2), 3.45 (q, 3H,
CH2), 2.10, 1.84 (s, 3H, ArACH3), 1.46 (t, 3H, CH3),
13C
NMR (100 MHz, CDCl3) d (ppm): 169.38 (C‚O, ester),
163.15 (C‚O, amide), 161.74 (C‚O, urea), 143.31 (C3),
142.64 (C5), 141.25, 137.48, 135.56, 133.39, 131.36, 130.63,
130.19, 129.83, 129.25, 128.91, 128.42, 125.54, 108.42 (C4),
56.44 (OACH2), 34.65 (CH2ANH), 22.17, 19.25 (ArACH3),
15.48, 12.06 (ACH3). Anal. Cal. for C24H26N4O4
(434,49 g/mol): C, 66.34; H, 6.03; N, 12.89. Found: C, 66.25;
H, 6.05; N, 12.95.Please cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
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pyridazine
A miliequimolar mixture of 1a,b and appropriate hydrazine
was refluxed in xylene for 24 h. After the solvent was removed
by evaporation, the oily residue was treated with ether and the
formed crude product was crystallized from appropriate
solvent.
2.2.25. 2-(2,5-Dimethylphenyl)-3,4,6-triphenyl-2H-pyrazolo
[3,4-d]pyridazin-7(6H)-one (4a)
(0.227 g, 45%), mp 224 C; (was crystallized from hexane); IR
(m, cm1): 3056 (aromatic CAH), 2920 (aliph. CAH), 1696
(C7),1650 (C4),
1H NMR (400 MHz, CDCl3) d (ppm): 7.89–
6.61 (m, 18H, ArAH), 2.23,1.82 (s, 3H, ArACH3),
13C NMR
(100 MHz, CDCl3) d (ppm): 162.40 (C7), 145.51 (C-7a),
144.36 (C3), 143.33 (C4), 140.84, 139.20, 138.38, 136.30,
133.81, 132.95, 131.35, 130.64, 129.69, 129.12, 128.68, 128.54,
128.12, 127.43, 126.76, 112.15 (C-3a), 18.76, 17.33 (ArACH3).
Anal. Cal. for C31H24N4O (468,55 g/mol): C, 79.46; H, 5.16;
N, 11.96. Found: C, 79.39; H, 5.15; N, 12.04.
2.2.25.1. 2-(2,5-Dimethylphenyl)-3,4-diphenyl-2H-pyrazolo
[3,4-d]pyridazin-7(6H)-one (4b). (0.16 g, 36%), mp 262 C;
(was crystallized from xylene/methanol); IR (m, cm1): 3421
(ANH), 3055 (aromatic CAH), 2985 (aliph. CAH), 1658
(C7), 1638 (C4),
1H NMR (400 MHz, CDCl3) d (ppm): 9.11
(s, 1H, ANH), 7.28–6.58 (m, 13H, ArAH), 2.23, 1.82 (s, 3H,
ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 160.67
(C7), 145.55 (C-7a), 144.41 (C3), 143.32 (C4), 140.21, 138.45,
136.78, 134.64, 133.13, 132.62, 130.23, 129.97, 129.65, 128.60,
128.15, 127.77, 127.32, 126.64, 110.72 (C-3a), 20.46, 17.31
(ArACH3). Anal. Cal. for C25H20N4O (392,45 g/mol): C,
76.51; H, 5.14; N, 14.28. Found: C, 76.43; H, 5.12; N, 14.33.
2.2.25.2. 2,6-Bis(2,5-dimethylphenyl)-3,4-diphenyl-2H-pyrazolo
[3,4-d]pyridazin-7(6H)-one (4c). (0.14 g, 25%), mp 194 C;
(was crystallized from xylene); IR (m, cm1): 3057 (aromatic
CAH), 2901 (aliph. CAH), 1664 (C7), 1632 (C4),
1H NMR
(400 MHz, CDCl3) d (ppm): 7.79–7.08 (m, 16H, ArAH),
2.28, 2.07 (s, 3H, ArACH3),
13C NMR (100 MHz, CDCl3) d
(ppm): 162.73 (C7), 146.18 (C-7a), 145.32 (C3), 144.38 (C4),
143.32, 143.07, 142.86, 139.63, 139.44, 139.11, 134.20, 133.44,
132.71, 132.31, 130.51, 130.42, 129.95, 129.33, 128.93, 128.51,
127.63, 127.20, 126.81, 124.51, 122.26, 110.05 (C-3a), 21.51,
17.33 (ArACH3). Anal. Cal. for C33H28N4O (496,60 g/mol):
C, 79.81; H, 5.68; N, 11.28. Found: C, 79.71; H, 5.69; N, 11.37.
2.2.25.3. 2-(2,5-Dimethylphenyl)-6-(3,4-dimethylphenyl)-3,4-
diphenyl-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (4d). (0.17 g,
30%), mp 187 C; (was crystallized from xylene); IR (m,
cm1): 3041 (aromatic CAH), 2914 (aliph. CAH), 1675 (C7),
1600 (C4),
1H NMR (400 MHz, CDCl3) d (ppm): 7.94–7.41
(m, 16H, ArAH), 2.40, 2.07 (s, 3H, ArACH3),
13C NMR
(100 MHz, CDCl3) d (ppm): 162.03 (C7), 145.93 (C-7a),
144.53 (C3), 143.23 (C4), 139.87, 139.10, 138.83, 138.72,
129.38, 129.12, 128.42, 128.12, 127.94, 127.41, 127.12, 126.33,
126.10, 124.35, 111.42 (C-3a), 20.45, 17.81 (ArACH3). Anal.
Cal. for C33H28N4O (496,60 g/mol): C, 79.81; H, 5.68; N,
11.28. Found: C, 79.69; H, 5.69; N, 11.38.icrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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diphenyl-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (4e). (0.24 g,
40%), mp 210 C; (was crystallized from chloroform/hexane);
IR (m, cm1): 3059 (aromatic CAH), 2925 (aliph. CAH), 1649
(C7),
13C NMR (400 MHz, CDCl3) d (ppm): 163.43 (C7),
145.66 (C-7a), 144.39 (C4), 141.35 (C3), 138.47, 136.73,
135.45, 133.30, 130.27, 129.94, 128.70, 128.54, 128.12, 127.28,
127.14, 125.12, 111.42 (C-3a), 20.45, 17.81 (ArACH3). Anal.
Cal. for C31H22N6O5 (558,54 g/mol): C, 66.66; H, 3.97; N,
15.05. Found: C, 66.55; H, 3.95; N, 15.17.
2.2.25.5. 2-(2,5-Dimethylphenyl)-3,4-diphenyl-6-(2,4,6-tri-
chlorophenyl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (4f).
(0.213 g, 37%), mp 217 C; (was crystallized from chloro-
form/hexane); IR (m, cm1): 3060 (aromatic CAH), 2925
(aliph. CAH), 1670 (C7),
13C NMR (100 MHz, CDCl3) d
(ppm): 161.56 (C7), 145.47 (C-7a), 142.24 (C3), 137.81 (C4),
136.73, 133.84, 132.62, 131.52, 131.00, 129.83, 129.48, 129.39,
129.26, 129.14, 128.71, 128.25, 127.35, 125.47, 121.62, 108.51
(C-3a), 19.35, 17.12 (ArACH3). Anal. Cal. for C31H21N4OCl
(571,88 g/mol): C, 65.11; H, 3.70; N, 9.80. Found: C, 65.03;
H, 3.71; N, 9.85.
2.2.25.6. 2-(2,5-Dimethylphenyl)-3,4-diphenyl-6-(4-(trifluo-
romethyl)phenyl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one
(4g). (0.26 g, 45%), mp 219 C; (was crystallized from ether/
hexane); IR (m, cm1): 3080 (aromatic CAH), 2840 (aliph.
C–H), 1673 (C7),
13C NMR (100 MHz, CDCl3) d (ppm):
163.45 (C7), 144.34 (C-7a), 143.81 (C3), 142.54 (C4), 141.47,
138.39, 136.56, 135.63, 133.72, 132.16, 130.90, 130.75, 129.82,
129.73, 129.44, 129.20, 129.04, 128.61, 127.76, 127.32, 121.85,
108.41 (C-3a), 20.39, 17.41 (ArACH3). Anal. Cal. for C23H23-
N4OF3 (536,55 g/mol): C, 71.63; H, 4.32; N, 10.44. Found: C,
71.56; H, 4.33; N, 10.51.
2.2.25.7. 2-(2,5-Dimethylphenyl)-4-ethoxy-3,6-diphenyl-2H-
pyrazolo[3,4-d]pyridazin-7(6H)-one (4h). (0.23 g, 50%), mp
205 C; (was crystallized from toluene); IR (m, cm1): 3090
(aromatic CAH), 2980 (aliph. CAH), 1722 (C7),
1H NMR
(400 MHz, CDCl3) d (ppm): 7.74–6.43 (m, 13H, ArAH), 3.79
(q, 2H, ACH2), 2.07, 1.81 (s, 3H, ArACH3), 1.76 (t, 3H,
ACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 164.72 (C7),
147.68 (C4), 144.32 (C-7a), 142.12 (C3), 135.45, 134.59,
133.30, 132.35, 131.27, 130.12, 129.63, 129.07, 128.54, 127.31,
126.18, 118.32 (C-3a), 61.28 (ACH2), 21.47, 17.47 (ArACH3),
14.36 (-CH3). Anal. Cal. for C27H24N4O2 (436,51 g/mol): C,
74.29; H, 5.54; N, 12.84. Found: C, 74.20; H, 5.55; N, 12.91.
2.2.25.8. 2-(2,5-Dimethylphenyl)-4-ethoxy-3-phenyl-2H-pyra-
zolo[3,4-d]pyridazin-7(6H)-one (4i). (0.27 g, 65%), mp
140 C; (was crystallized from toluene); IR (m, cm1): 3026
(aromatic CAH), 2946 (aliph. CAH), 1645 (C7),
1H NMR
(400 MHz, CDCl3) d (ppm): 7.96–7.29 (m, 8H, ArAH), 5.11
(s, 1H, ANH), 3.51 (q, 2H, ACH2), 1.82, 1.47 (s, 3H,
ArACH3), 1.22 (t, 3H, ACH3),
13C NMR (100 MHz, CDCl3)
d (ppm): 161.52 (C7), 144.20 (C4), 142.74 (C-7a), 142.15 (C3),
141.51, 136.63, 134.28, 132.45, 131.52, 130.39, 129.64, 129.06,
128.31, 127.44, 126.36 (C-3a), 60.35 (OACH2), 22.64, 17.85
(ArACH3), 14.25 (ACH3). Anal. Cal. for C21H20N4O2
(360,41 g/mol): C, 69.98; H, 5.59; N, 15.55. Found: C, 69.90;
H, 5.60; N, 15.63.Please cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
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pyrazolo[3,4-d]pyridazin-7(6H)-one (4j). (0.15 g, 30%); mp
190 C; (was crystallized from chloroform/hexane); IR (m,
cm1): 3061 (aromatic CAH), 2979 (aliph. CAH), 1713 (C7),
1633 cm1 (C4),
1H NMR (400 MHz, CDCl3) d (ppm): 7.7–
6.4 (m, 11H, ArAH), 4.2 (q, 2H, ACH2), 2.5, 1.5 (s, 3H,
ArACH3), 1.1 (t, 3H, ACH3),
13C NMR (100 MHz, CDCl3)
d (ppm): 165.27 (C7), 146.38 (C4), 144.12 (C-7a), 139.25 (C3),
137.10, 129.64, 129.56, 129.48, 129.26, 128.74, 128.61, 128.43,
128.32, 128.15, 110.71 (C-3a), 61.45 (ACH2), 21.35, 17.28
(ArACH3) 13.56 (ACH3). Anal. Cal. for C29H28N4O2
(464,56 g/mol): C, 74.98; H, 6.08; N, 12.06. Found: C, 74.85;
H, 6.09; N, 12.15.
2.2.25.10. 2-(2,5-Dimethylphenyl)-6-(3,4-dimethylphenyl)-4-
ethoxy-3-phenyl-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (4k).
(0.15 g, 30%), mp 220 C; (was crystallized from chloroform/
hexane); IR (m, cm1): 3020 (aromatic CAH), 2975 (aliph.
CAH), 1724 (C7), 1633 cm
1 (C4),
1H NMR (400 MHz,
CDCl3) d (ppm): 7.7–6.5 (m, 11H, ArAH), 4.1 (q, 2H,
ACH2), 2.3, 1.6 (s, 3H, ArACH3), 1.1 (t, 3H, ACH3),
13C
NMR (100 MHz, CDCl3) d (ppm): 163.11 (C7), 145.14 (C4),
144.39 (C-7a), 136.09 (C3), 136.45, 135.49, 132.20, 130.44,
129.96, 129.48, 129.12, 128.39, 128.26, 126.32, 114.18 (C-3a),
61.20 (ACH2), 18.74, 17.21 (ArACH3), 14.14 (ACH3). Anal.
Cal. for C29H28N4O2 (464,56 g/mol): C, 74.98; H, 6.08; N,
12.06. Found: C, 74.89; H, 6.07; N, 12.14.
2.2.25.11. 2-(2,5-Dimethylphenyl)-6-(2,4-dinitrophenyl)-4-
ethoxy-3-phenyl2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (4l).
(0.25 g, 45%), mp 194 C; (was crystallized from chloroform/
n-hexane); IR (m, cm1): 3088 (aromatic CAH), 2925 (aliph.
CAH), 1631 (C7), 1615 (C4),
13C NMR (100 MHz, CDCl3) d
(ppm): 161.95 (C7), 145.76 (C4), 144.53 (C-7a), 143.71 (C3),
136.40, 136.18, 135.32, 134.36, 133.38, 132.60, 131.22, 130.85,
130.66, 129.72, 129.61, 129.30, 129.11, 128.86, 128.68, 128.17,
127.19, 125.62, 114.25 (C-3a), 50.14 (OACH2), 20.62, 17.20
(ArACH3), 13.86, (ACH3). Anal. Cal. for C27H22N6O6
(526,50 g/mol): C, 61.59; H, 4.21; N, 15.96. Found: C, 61.51;
H, 4.18; N, 16.09.
2.2.25.12. 2-(2,5-Dimethylphenyl)-4-ethoxy-3-phenyl-6-(2,4,6-
trichlorophenyl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one (4m).
(0.19 g, 40%), mp 170 C; (was crystallized from chloroform/
hexane); IR (m, cm1): 3026 (aromatic CAH), 2956 (aliph.
CAH), 1684 (C7), 1634 cm
1 (C4),
13C NMR (100 MHz,
CDCl3) d (ppm): 162.43 (C7), 144.53 (C4), 143.72 (C-7a),
142.64 (C3), 141.44, 139.63, 136.71, 135.53, 133.72, 132.10,
130.75, 130.43, 129.91, 129.63, 129.54, 129.30, 128.87, 128.69,
126.84, 121.44 (C-3a), 49.74 (O-CH2), 19.35, 17.43 (ArACH3),
14.02 (ACH3). Anal. Cal. for C27H21N4O2Cl3 (539,84 g/mol):
C, 60.07; H, 3.92; N, 10.38. Found: C, 59.96; H, 3.93; N, 10.51.
2.2.25.13. 2-(2,5-Dimethylphenyl)-4-ethoxy-3-phenyl-6-(4-(tri-
fluoromethyl)phenyl)-2H-pyrazolo[3,4-d]pyridazin-7(6H)-one
(4n). (0.22 g, 40%), mp 158 C; (was crystallized from chloro-
form/hexane); IR (m, cm1): 3040 (aromatic CAH), 2950
(aliph. CAH), 1723 (C7), 1615 cm
1 (C4),
13C NMR
(100 MHz, CDCl3) d (ppm): 162.84 (C7), 146.38 (C4), 144.35
(C-7a), 143.19 (C3), 140.76, 139.34, 137.43, 135.58, 133.31,
132.56, 131.69, 129.74, 129.40, 129.29, 129.12, 128.73, 128.45,icrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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17.24 (ArACH3), 13.40 (ACH3). Anal. Cal. for C28H23N4O2F3
(504,50 g/mol): C, 66.66; H, 4.60; N, 11.11. Found: C, 66.57;
H, 4.62; N, 11.19.
2.2.25.14. 1-(2,5-Dimethylphenyl)-5-phenyl-1H-pyrazole-3,4-
dicarboxylic acid (5). Compound 1b 0.364 g (1 mmole) was
refluxed in solution of 0.1 g (2.5 mmole) NaOH for about
1.5 h. Mixed solution was cooled down to room temperature.
It was stirred for a while by adding 1.5 mL concentrated
HCl and water at equal volume. Precipitated white solid pro-
duct was filtered and washed with water again. It was crystal-
lized from butanol (0,384 g, 85%), mp 100 C; IR (m, cm1):
3392 (b, AOH), 3058–3022 (aromatic CAH), 2976 (aliph.
CAH), 1716–1683 (C‚O, acide), 1H NMR (400 MHz, CDCl3)
d (ppm): 10.37, 9.88 (b, 1H, AOH), 7.80–7.09 (m, 8H, ArAH),
2.30, 1.74 (s, 3H, ArACH3),
13C NMR (100 MHz, CDCl3) d
(ppm): 167.78, 164.57 C‚O, acide, 145.03 (C3), 143.06 (C5),
133.72, 131.17, 130.86, 130.61, 129.77, 129.53, 129.13, 128.94,
128.41, 127.73, 127.66, 127.14, 110.26 (C4), 27.18, 19.21
(ArACH3). Anal. Cal. for C19H16N2O4 (336,34 g/mol): C,
67.85; H, 4.79; N, 8.33. Found: C, 67.79; H, 4.78; N, 8.41.
2.2.26. 1-(2,5-Dimethylphenyl)-5-phenyl-1H-pyrazole-3,4-
dicarbonyl dichloride (6)
Compound 6 was prepared according to the general procedure
for synthesis of acylchlorur. (0.4 g, 68%), mp 98 C; (was crys-
tallized from chloroform/n-hexane); IR (m, cm1): 3058 (aro-
matic CAH), 2969 (aliph. CAH), 1716, 1683 (C‚O, acyl),
1H NMR (400 MHz, CDCl3) d (ppm): 8.19–7.11 (m, 8H,
ArAH), 2.22, 1.82 (s, 3H, ArACH3),
13C NMR (100 MHz,
CDCl3) d (ppm): 166.00, 163.00 (C‚O, acyl), 142.45 (C3),
141.81 (C5), 133.32, 131.34, 130.99, 130.16, 129.89, 129.56,
129.16, 128.66, 128.26, 126.88, 108.65 (C4), 23.30, 17.26
(ArACH3), MS (m/z): Calc. = 372.0, Found = 372.1.
2.2.27. Dimethyl 1-(2,5-dimethylphenyl)-5-phenyl-1H-pyrazole-
3,4-dicarboxylate (7a)
Compound 7a was prepared according to the general proce-
dure for synthesis of ester. (0.35 g, 84%), mp 140 C; (was
crystallized from methanol); IR (m, cm1): 3026 (aromatic
CAH), 2951 (aliph. CAH), 1724 (C‚O, ester), 1H NMR
(400 MHz, CDCl3) d (ppm): 7.90–6.59 (m, 8H, ArAH), 3.66
(s, 3H, CH3), 2.04, 1.84 (s, 3H, ArACH3),
13C NMR
(100 MHz, CDCl3) d (ppm): 166.50, 163.46 (C‚O, ester),
145.18 (C3), 143.73 (C5), 140.41, 138.26, 136.35, 132.80,
131.67, 130.52, 129.15, 128.33, 124.64, 110.55 (C4), 47.50
(CH3), 21.51, 17.49 (ArACH3). Anal. Cal. for C21H20N2O4
(364,39 g/mol): C, 69.22; H, 5.53; N, 7.69. Found: C, 69.16;
H, 5.54; N, 7.75.
2.2.28. Diethyl 1-(2,5-dimethylphenyl)-5-phenyl-1H-pyrazole-
3,4-dicarboxylate (7b)
Compound 7b was prepared according to the general proce-
dure for synthesis of ester. (0.324 g, 73%), mp 118 C; (was
crystallized from ethanol); IR (m, cm1):3060–3022 (aromatic
CAH), 2979–2919 (aliph. CAH), 1717 (C‚O, ester), 1H
NMR (400 MHz, CDCl3) d (ppm): 7.42–6.39 (m, 8H, ArAH),
4.43 (q, 2H, CH2), 2.22, 1.81 (s, 3H, ArACH3), 1.44 (t, 3H,
CH3),
13C NMR (100 MHz, CDCl3) d (ppm): 163.22, 159.67
(C‚O, ester), 143.71 (C3), 141.40 (C5), 139.21, 135.39,Please cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
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49.15, 44.34 (CH2), 19.28, 17.41 (ArACH3), 12.53, 11.70
(CH3). Anal. Cal. for C23H24N2O4 (392,45 g/mol): C, 70.39;
H, 6.16; N, 7.14. Found: C, 70.32; H, 6.18; N, 7.22.
2.2.29. N3,N4-Dicarbamoyl-1-(2,5-dimethylphenyl)-5-phenyl-
1H-pyrazole-3,4-dicarboxyamide (7c)
Compound 7c was prepared according to the general proce-
dure for synthesis of urea. (0.3 g, 59%), mp 240 C; (was crys-
tallized from ether/n-hexane); IR (m, cm1): 3407–3153 (b,
NAH), 3056 (aromatic CAH), 2946 (aliph. CAH), 1646
(C‚O, urea), 1H NMR (400 MHz, CDCl3) d (ppm): 9.38 (b,
1H, NH), 7.84–6.49 (m, 8H, ArAH), 5.68, 5.40 (s, 2H,
ANH2), 2.23, 1.85 (s, 3H, ArACH3),
13C NMR (100 MHz,
CDCl3) d (ppm): 168.04, 164.77 (C‚O, amide), 164.43,
160.35 (C‚O, urea), 148.84 (C3), 146.49 (C5), 143.11,
141.31, 136.46, 135.00, 134.57, 133.97, 133.33, 130.81, 129.69,
128.86, 127.56, 114.02 (C4), 24.81, 17.23 (ArACH3). Anal.
Cal. for C21H20N6O4 (420,42 g/mol): C, 59.99; H, 4.79; N,
19.99. Found: C, 59.89; H, 4.76; N, 20.09.
2.2.30. N3,N4-Methyl(carbamoyl)1-(2,5-dimethylphenyl)-5-
phenyl-1H-pyrazole-3,4-dicarboxyamide (7d)
Compound 7d was prepared according to the general proce-
dure for synthesis of urea. (0.35 g, 65%), mp 258 C; (was crys-
tallized from ether/n-hexane); IR (m, cm1): 3336 (b, NAH),
3040 (aromatic CAH), 2822 (aliph. CAH), 1694 (C‚O, urea),
1H NMR (400 MHz, CDCl3) d (ppm): 9.18, 8.95 (b, 1H, NH),
7.86–6.91 (m, 8H, Ar‚H), 6.19, 5.84 (q, 1H, ‚NH), 2.61 (d,
3H, CH3), 2.08, 1.73 (s, 3H, Ar‚CH3),
13C NMR (100 MHz,
CDCl3) d (ppm): 166.41, 163.26 (C‚O, amide), 161.54, 157.39
(C‚O, urea), 145.62 (C3), 141.16 (C5), 140.03, 136.72, 134.40,
133.36, 132.91, 131.16, 130.23, 129.48, 128.36, 127.52, 126.74,
109.45 (C4), 36.70 (CH3), 24.81, 17.23 (ArACH3). Anal. Cal.
for C23H24N6O4 (448,47 g/mol): C, 61.60; H, 5.39; N, 18.74.
Found: C, 61.53; H, 5.40; N, 18.81.
2.2.31. 1-(2,5-Dimethylphenyl)-5-phenyl-1H-pyrazole-3,4-
dicarboxyamide (7e)
Compound 7e was prepared according to the general proce-
dure for synthesis of amide. (0.3 g, 70%), mp 228 C; (was
crystallized from methanol); IR (m, cm1): 3446–3152 (b,
ANH2), 3055 (aromatic CAH), 2923 (aliph. CAH), 1672
(C‚O, amide), 1H NMR (400 MHz, CDCl3) d (ppm): 7.79–
6.61 (m, 8H, ArAH), 5.23, 5.12 (s, 2H, ANH2), 2.23, 1.82 (s,
3H, ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm):
166.19, 163.84 (C‚O, amide), 145.62 (C3), 141.25 (C5),
133.34, 131.45, 130.91, 129.95, 129.72, 128.86, 128.58, 128.26,
126.61, 113.18 (C4), 21.14,18.90 (ArACH3). Anal. Cal. for
C19H18N4O2 (334,37 g/mol): C, 68.25; H, 5.43; N, 16.76.
Found: C, 68.19; H, 5.44; N, 16.83.
2.2.32. 1-(2,5-Dimethylphenyl)- N3,N4-diethyl-5-phenyl-1H-
pyrazole-3,4-dicarboxyamide (7f)
Compound 7f was prepared according to the general proce-
dure for synthesis of amide. (0.33 g, 69%), mp 182 C; (was
crystallized from n-hexane/chloroform); IR (m, cm1): 3396
(b, NAH), 3030 (aromatic CAH), 2979 (aliph. CAH), 1640
(C‚O, amide), 1H NMR (400 MHz, CDCl3) d (ppm): 9.65,
9.89 (t, 1H, NH), 7.99–6.85 (m, 8H, ArAH), 3.75 (q, 2H,icrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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13C NMR
(100 MHz, CDCl3) d (ppm): 164.18, 161.35 (C‚O, amide),
144.20 (C3), 141.52 (C5), 133.74, 130.45, 129.63, 129.24,
128.76, 128.52, 128.43, 128.22, 128.10, 113.18 (C4), 51.50
(CH2), 20.42,17.30 (ArACH3), 14.12, 12.68 (CH3). Anal. Cal.
for C23H26N4O2 (390,48 g/mol): C, 70.75; H, 6.71; N, 14.35.
Found: C, 70.68; H, 6.73; N, 14.43.
2.2.33. 1-(2,5-Dimethylphenyl)-N3,N4,5-triphenyl-1H-pyrazole-
3,4-dicarboxyamide (7g)
Compound 7g was prepared according to the general proce-
dure for synthesis of amide. (0.2 g, 35%), mp 211 C; (was
crystallized from n-hexane/chloroform); IR (m, cm1): 3345
(b, NAH), 3040 (aromatic CAH), 2807 (aliph. CAH), 1652
(C‚O, amide), 13C NMR (100 MHz, CDCl3) d (ppm):
163.59, 162.65 (C‚O, amide), 144.74 (C3), 144.39 (C5),
134.13, 133.36, 132.40, 130.73, 130.24, 129.51, 129.31, 129.06,
128.58, 128.14, 127.63, 112.45 (C4), 18.24, 17.38 (ArACH3).
Anal. Cal. for C31H26N4O2 (486,56 g/mol): C, 76.52; H, 5.39;
N, 11.51. Found: C, 76.41; H, 5.41; N, 11.59.
2.2.34. 4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-3-carbonitrile (8a)
A cold solution of the acid amide 3c (0.421 g, 1 mmole) in a
mixture of DMF (0.7 mL) and SOCl2 (0.15 mL) was stirred
at 0–5 C for 2 h. After heating to room temperature, stirring
was continued overnight, then the reaction mixture was poured
over crushed ice and the separated solid isolated by filtration,
washed with water and crystallized from toluene to give
0.417 g (68%) of 8a, mp 112 C; IR (m, cm1): 3046 (aromatic
CAH), 2921 (aliph. CAH), 2165 (ACN,), 1652 cm1 (C‚O,
benzoyl), 13C NMR (100 MHz, CDCl3) d (ppm): 188.68
(C‚O, benzoyl), 146.30 (C3), 145.13 (C5), 143.36, 139.12,
136.26, 134.46, 133.85, 130.38, 130.10, 129.83, 129.54, 129.46,
129.24, 128.74, 128.38, 127.10, 126.74, 122.21 (C4), 116.32
(C„N), 21.70, 17.37 (ArACH3). Anal. Cal. for C25H19N3O
(377,44 g/mol): C, 79.55; H, 5.07; N, 11.13. Found: C, 79.48;
H, 5.09; N, 11.20.
2.2.35. Ethyl 3-cyano-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazole-4-carboxylate (8b)
Compound 8b was prepared according to the general proce-
dure for synthesis of nitrile. (0.30 g, 24%), mp 158 C; (was
crystallized from isoamylalcohol/secondary butyl alcohol);
IR (m, cm1): 3050 (aromatic CAH), 2924 (aliph. CAH),
2162 cm1 (C„N, nitrile), 1717 cm1 (C‚O, ester), 1H
NMR (400 MHz, CDCl3) d (ppm): 7.68–6.74 (m, 8H, ArAH),
4.18 (q, 2H, CH2), 2.13, 1.79 (s, 3H, ArACH3), 1.18 (t, 3H,
CH3),
13C NMR (100 MHz, CDCl3) d (ppm): 168.38 (C‚O,
ester), 147.10 (C3), 146.55 (C5), 136.85, 133.72, 130.38,
130.10, 129.74, 129.54, 129.46, 129.24 129.10, 128.83, 128.24,
116.95 (C„N, nitrile), 107.75 (C4), 54.84 (CH2), 21.12, 18.77
(ArACH3), 14.13 (CH3). Anal. Cal. for C21H19N3O2
(345,39 g/mol): C, 73.03; H, 5.54; N, 12.17. Found: C, 72.96;
H, 5.53; N, 12.26.
2.2.36. 1-(2,5-Dimethylphenyl)-5-phenyl-1H-pyrazole-3,4-
dicarbonitrile (8c)
Compound 7e of 0.334 g (1 mmole) was dissolved in xylene.
5 mL DMF and 0.292 mL (4 mmole) SOCl2 was added inPlease cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
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water was added to the mixture. Precipitated solid product
was filtered and purified from ethanol–water mixture by crys-
tallization. (0.3 g, 30%), mp 217 C; IR (m, cm1): 3060 (aro-
matic C–H), 2923 (aliph. CAH), 2207, 2179 (C„N, nitrile),
1H NMR (400 MHz, CDCl3) d (ppm): 8.07–7.03 (m, 8H,
ArAH), 2.37, 2.13 (s, 3H, ArACH3),
13C NMR (100 MHz,
CDCl3) d (ppm): 145.25 (C3), 144.06 (C5), 142.92, 135.69,
133.32, 130.93, 129.98, 129.50, 128.56, 126.80, 125.74, 118.17,
116.12 (C„N), 110.40 (C4), 18.60, 17.36 (ArACH3), MS (m/
z): Calc. = 298.1, Found = 298.1.
2.2.37. 1-(2,5-Dimethylphenyl)-5-phenyl-1H-pyrazol-4-yl-
(phenyl)methanone (9a)
Compound 1a (0.397 g, 1 mmole) was heated to 210–220 C in
an oil bath for about 30 min without any solvent. After cooling
to room temperature, the residue was treated with ether to give
the crude product, which was crystallized from n-hexane, to
yield 0.32 g (80%); mp 175 C; IR (m, cm1): 3040 (aromatic
CAH), 2921 (aliph. CAH), 1649 (C‚O, benzoyl), 13C NMR
(100 MHz, DMSO-d6) d (ppm): 192.32 (C‚O, benzoyl),
145.25 (C3), 144.06(C5), 142.92, 132.32, 131.16, 130.93,
130.12, 129.93, 129.04, 128.95, 128.84, 128.46, 128.25, 128.03,
127.60, 126.74, 120.11 (C4), 23.24, 18.04 (ArACH3). Anal.
Cal. for C24H20N2O (352,43 g/mol): C, 81.79; H, 5.72; N,
7.95. Found: C, 81.71; H, 5.74; N, 8.04.
2.2.38. Ethyl 1-(2,5-dimethylphenyl)-5-phenyl-1H-pyrazole-4-
carboxylate (9b)
Compound 1b (0.364 g, 1 mmole) was heated to 210–220 C in
an oil bath for about 30 min without any solvent. After cooling
to room temperature, the residue was treated with ether to give
the crude product, which was crystallized from ethanol, to
yield 0.27 g (75%), mp 145 C; IR (m, cm1): 3025 (aromatic
CAH), 2918 (aliph. CAH), 1723 (C‚O, ester), 1H NMR
(400 MHz, CDCl3) d (ppm): 7.87–7.11 (m, 8H, ArAH), 3.82
(q, 2H, ACH2), 2,19, 1.75 (s, 3H, ArACH3), 1.41 (t, 3H,
ACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 163.56
(C‚O, ester), 144.19 (C3), 142.51 (C5),141.63, 136.66,
136.23, 133.70, 133.64, 131.29, 130.93, 129.60, 129.20, 128.31,
127.56, 125.28, 113.21 (C4), 59.70 (ACH2), 21.98, 18.15
(ArACH3), 14.22 (ACH3). Anal. Cal. for C20H20N2O2
(320,38 g/mol): C, 74.98; H, 6.29; N, 8.74. Found: C, 74.89;
H, 6.31; N, 8.81.
2.2.39. 1-(2,5-Dimethylphenyl)-5-phenyl-1H-pyrazole-4-
carboxylic acid (9c)
Compound 9c can be synthesized in two different methods.
Method A: Compound 5 of 0.336 g (1 mmole) was heated at
200 C until carbon dioxide gas exiting finished. The residue
solid was washed with ether and mixed 2 h in room tempera-
ture from n-hexane/ether by crystallization (0.25 g, 71%).
Method B: Compound 9a of 0.320 g (1 mmole) was refluxed
in a solution of 0.1 g (2.5 mmole) NaOH for about 2 h. Mixed
solution was cooled down to room temperature. It was stirred
for a while by adding 1.5 mL concentrated HCl and water at
equal volume. Precipitated solid product was filtered and
washed with water again. It was crystallized from n-hexane/
ether. (0,28 g, 80%), mp 207 C; IR (m, cm1): 3390 (b,
AOH), 3057 (aromatic CAH), 2974 (aliph. CAH), 1732icrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
10 A. C¸etin, _I. Bildirici(C‚O, acide), 1H NMR (400 MHz, CDCl3) d (ppm): 13.75 (b,
1H, AOH), 8.18–6.35 (m, 9H, ArAH), 2.27, 1.80 (s, 3H,
ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 165.73
(C‚O, acide), 144.21 (C3), 143.55 (C5), 141.55, 141.47,
138.54, 136.34, 131.72, 130.62, 129.48, 129.36, 127.45, 126.63,
122.52 (C4), 21.63, 17.58 (ArACH3).
2.2.40. 1-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazol-3-yl)-3-(2-hydroxy-4-methyl-phenyl)-propane-1,3-
dione (10)
Compound 2a of 0.403 g (1 mmole) was dissolved in pyridine
(5 mL), the 2-hydroxy-4-methyl-acethophenone 0.150 g
(1 mmole) was added and refluxed for 2 h. KOH (0.56 g,
10 mmole) was added to the reaction pot and refluxed for
2 h. During the second period of refluxing, the product was
precipitated. After finishing the reaction, 3 M HCl 20 (mL)
was added to the cooled solution for neutralizing. The formed
precipitated product was filtered and the crude product was
from n-hexane/chloroform by crystallization. (0.46 g, 70%),
mp 184 C; IR (m, cm1): 3229 cm1 (phenolic AOH), 3060
(aromatic CAH), 2929 (aliph. CAH), 1709 (C‚O), 1637
(C‚O, benzoyl), 1H NMR (400 MHz, DMSO) d (ppm): 8.8
(br, enolform, AOH) 8.2–6.5 (m, ArAH), 6.3 (enolform,
C‚CH), 5.5 (br, PhAOH), 3.5 (s, ketoform ACH2), 2.1, 1.7
(s, ArACH3), 1.2 (PhACH3),
13C NMR (100 MHz, DMSO)
d (ppm): 205.1, 195.0, 193.2 (C‚O), 161.1, 145.6 (C3), 144.3
(C5), 139.8, 136.6, 135.2, 134.2, 133.1, 132.7, 131.2, 130.8,
130.1, 129.9, 129.2, 128.7, 118.2, 109.0 (C4), 92.8 (enolform,
‚CHA), 45.1 (ketoform, CH2), 27.0 (PhACH3), 20.0, 17.0
(ArACH3), MS (m/z): Calc. = 528.2, Found = 528.2.
2.2.41. 2-(4-Benzoyl-1-(2,5-dimethylphenyl)-5-phenyl-1H-
pyrazol-3-yl)-7-methyl-4H-chromen-4-one (11)
Compound 10 of 0.528 g (1 mmole) was dissolved in concen-
trated H2SO4 (2 mL). The reaction was stirred for 6 h at rt.
After TLC monitoring, water (10 mL) was added partly to
the mixture on ice bath. The formed precipitated product
was filtered and the crude product was from ethanol by crystal-
lization. (0,3 g, 75%), mp 215 C; IR (m, cm1): 3060 (aromatic
CAH), 2917 (aliph. CAH), 1709 (C‚O), 1637 (C‚O, ben-
zoyl), 1H NMR (400 MHz, DMSO) d (ppm): 7.8–7.0
(m, ArAH), 6.4 (s, C‚CH), 2.1, 1.8 (s, ArACH3), 1.1
(s, PhACH3),
13C NMR (100 MHz, DMSO) d (ppm): 196.34
(C‚O, benzoyl), 173.10 (C‚O), 158.35, 146.28 (C3), 143.35
(C5), 143.13, 140.35, 135.61, 135.37, 132.82, 131.53, 131.19,
130.21, 129.61, 129.32, 129.10, 128.82, 128.44, 127.95, 126.62,
109.0 (C4), 29.70 (CH3), 23.03, 18.79 (ArACH3), MS (m/z):
Calc.= 510.19, Found = 510.2.
2.2.42. 1-(2,5-Dimethylphenyl)-5-phenyl-1H-pyrazole-3,4-
diyl)-(bisphenylmethanone) (12)
Compound 12 can be synthesized in two different methods.
Method A: Compound 2a of 0.414 g (1 mmole) was dis-
solved in dry benzene and 0.33 g (2.5 mmole) AlCl3was
added to this solution. After cooling down of mixture which
was refluxed for 3 h, organic phase was separated by adding
some ether and ice water. Then ether was evaporated and the
residue solid was crystallized from n-hexane/ether (0.27 g,
41%).
Method B: Compound 6 of 0.372 g (1 mmole) was dissolved
in dry benzene and 0.33 g (2.5 mmole) AlCl3 was added to thisPlease cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
http://dx.doi.org/10.1016/j.jscs.2016.05.008solution. After cooling down of mixture which was refluxed for
3 h, organic phase was separated by adding some ether and ice
water. Then ether was evaporated and the residue solid was
crystallized from n-hexane/ether. (0.2 g, 30%), mp 292 C;
IR (m, cm1): 3057, 3028 (aromatic CAH), 2923 (aliph.
CAH), 1707 (C‚O, benzoyl), 1H NMR (400 MHz, CDCl3)
d (ppm): 7.67–6.52 (m, 18H, ArAH), 2.06, 1.83 (s, 3H,
ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm): 191.42,
189.38 (C‚O, benzoyl), 145.24 (C3), 144.55 (C5), 140.66,
139.37, 138.39, 136.26, 133.74, 132.82, 131.41, 130.65, 129.73,
129.26, 129.09, 128.54, 128.37, 127.61, 127.43, 126.35, 109.24
(C4), 21.31, 17.56 (ArACH3). Anal. Cal. for C31H24N2O2
(456,53 g/mol): C, 81.56; H, 5.30; N, 6.14. Found: C, 81.50;
H, 5.28; N, 6.19.
2.2.43. 2-(2,5-Dimethylphenyl)-3,4,7-triphenyl-2H-pyrazolo
[4,3-d]pyridazine (13)
Compound 12 0.456 g (1 mmole) was dissolved in dry toluene
and 0.032 g (1 mmole) anhydrous hydrazine was added and
refluxed for 5 h. Then, solvent was evaporated and 10 mL
ether was added to residue product and stirred for an hour.
Precipitated product was filtered and purified from ether/chlo-
roform mixture by crystallization. (0,27 g, 70%), mp 241 C;
IR (m, cm1): 3030 (aromatic CAH), 2945 (aliph. CAH), 1H
NMR (400 MHz, DMSO) d (ppm): 7.76–6.38 (m, 18H,
ArAH), 2,06, 1.75 (s, 3H, ArACH3),
13C NMR (100 MHz,
DMSO) d (ppm): 164.71 (C7), 160.43(C4), 148.68 (C-7a),
146.35 (C3), 143.24, 141.52, 136.45, 135.07, 134.63, 133.89,
133.40, 132.21, 131.32, 130.91, 130.66, 130.15, 129.72, 129.31,
129.02, 128.80, 128.34, 128.09, 127.63, 127.47, 127.15, 109.12
(C-3a), 21.73, 18.86 (ArACH3), MS (m/z): Calc. = 452.2,
Found = 452.2.
2.2.44. 2-(2,5-Dimethylphenyl)-3-phenyl-5,6-dihydro-2H-
pyrazolo[4,3-d] pyridazine-4,7-dione (14)
Compound 7a 0.336 g (1 mmole) was dissolved in 10 mL dry
toluene and anhydrous hydrazine was added at 1/1 mol rate.
The mixture was refluxed for about 5 h. Precipitate white pro-
duct was filtered and purified from n-hexane/chloroform mix-
ture by crystallization. (0,2 g, 51%), mp 320 C; IR (m, cm1):
3254(NAH), 3026 (aromatic CAH), 2947 (aliph. CAH), 1656
(C‚O, amide), 1H NMR (400 MHz, DMSO) d (ppm): 9.30,
9.13 (b, 1H, NH), 7.85–7.45 (m, 8H, ArAH), 2.28, 1.80 (s,
3H, ArACH3),
13C NMR (100 MHz, DMSO) d (ppm):
165.49 (C7), 163.50 (C4), 145.21 (C-7a), 145.21 (C3), 144.38
(C4), 143.76, 136.27, 135.89, 132.64, 130.41, 129.73, 128.36,
127.48, 126.25 (C-3a), 22.15, 17.63 (ArACH3), MS (m/z):
Calc. = 332.1, Found = 332.1.
2.2.45. 2-(2,5-Dimethylphenyl)-3-phenyl-2H-pyrazolo[4,3-d]
pyridazine-4,7-diamine (15)
Compound 8c 0.372 g (1 mmole) was dissolved in 10 mL anhy-
drous ethanol. 0.016 g (0.5 mmole) anhydrous hydrazine was
added and refluxed for 5 h. The solvent was evaporated and
residue compound was washed with ether and water. The
crude product was from ethanol by crystallization. (0,22 g,
75%), mp > 320 C; IR (m, cm1): 3324 (ANH2), 3058 (aro-
matic CAH), 2922 (aliph. CAH), 1H NMR (400 MHz, CDCl3)
d (ppm): 8.18–6.35 (m, 8H, ArAH), 4.89, 4.72 (CANH), 2.28,
1.81 (s, 3H, ArACH3),
13C NMR (100 MHz, CDCl3) d (ppm):
163.34 (C7), 163.15 (C4), 145.54 (C-7a), 144.39 (C3), 136.09icrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
Synthesis and antimicrobial activity of 4-acyl-pyrazoles 11(C-3a), 135.43, 133.34, 132.61, 130.34, 129.51, 129.12, 128.35,
127.54, 126.45, 114.18 (C-3a), 18.79, 17.21 (ArACH3). Anal.
Cal. for C19H18N6 (330,39 g/mol): C, 69.07; H, 5.49; N,
25.44. Found: C, 68.98; H, 5.51; N, 25.51.
2.2.46. 2-(2,5-Dimethylphenyl)-3,4-diphenylpyrazolo[4,3d]
[1,2]oxazin-7(2H)-one (16)
Compound 1a 0.199 g (0.5 mmole) and excess of hydroxyl
amine were heated 150 C on an oil for 1 h. After cooling to
room temperature, the resulting mixture was first washed with
water then treated with ether and the formed precipitated pro-
duct was filtered and the crude product was from n-hexane/
chloroform by crystallization. (0.15 g, 65%), mp 130 C; IR
(m, cm1): 3057 (aromatic CAH), 2925 (aliph. CAH), 1684
(C7),
1H NMR (400 MHz, DMSO) d (ppm): 7.7–6.5 (m,
13H, ArAH), 2.19, 1.72 (s, 3H, ArACH3),
13C NMR
(100 MHz, DMSO) d (ppm): 164.61 (C7), 162.13 (C4),
144.21 (C3), 141.39 (C5), 137.12, 133.62, 131.52, 130.56,
130.21, 129.80, 129.14, 128.79, 126.32, 121.12, 109.15 (C-3a),
22.70, 17.09 (ArACH3). Anal. Cal. for C25H19N3O2
(393,44 g/mol): C, 76.32; H, 4.87; N, 10.68. Found: C, 76.26;
H, 4.86; N, 10.77.
2.2.47. 4-Benzoyl-1-(2-carboxy-5-methylphenyl)-5-phenyl-1H-
pyrazole-3-carboxylic acid (17)
Compound 1a of 0.397 gr (1 mmole) was transferred to a
flask. 0.524 g (2 mmole) Na2Cr2O7 and 1,5 mL water were
added the mixture was stirred at room temperature by an
hour, 3 drops of 10 to 12 times with an interval of 15 min
was added H2SO4 and mixed for 24 h and water was added.
Then the crude precipitate was isolated by filtration and crys-
tallized from DMSO to give 0.46 g (70%) of 17, mp 217 C;
IR (m, cm1): 3391 (b, AOH), 3051 (aromatic CAH), 2922
(aliph. CAH), 1713 (AOH, COOH), 1663 (C‚O, benzoyl),
1H NMR (400 MHz, CDCl3) d (ppm): 10.2 (b, 1H, AOH),
7.9–6.5 (m, 13H, ArAH), 1.81 (s, 3H, ArACH3),
13C NMR
(100 MHz, CDCl3) d (ppm): 191.44 (C‚O, benzoyl), 162.74,
160.02 (C‚O, acide), 144.73 (C3), 144.39 (C5), 139.90,
138.52, 137.30, 136.65, 135.48, 134.81, 132.80, 132.53,
129.66, 129.45, 129.13, 128.41, 127.38, 127.12, 125.32, 121.97
(C4), 18.84 (ArACH3). Anal. Cal. for C25H18N2O5
(426,42 g/mol): C, 70.42; H, 4.25; N, 6.57. Found: C, 70.34;
H, 4.24; N, 6.67.
2.2.48. 2-(2,5-Dimethylphenyl)-3-phenyl-2H-furo[3,4-c]
pyrazole-4,6-dione (18)
Compound 5 of 0.336 g (1 mmole) was dissolved in a mixture
of DMF (0.3 mL) and SOCl2 (1.4 mL) and the reaction was
stirred at 0–5 C for 4 h. After heating to room temperature,
stirring was continued overnight, then the reaction mixture
was poured over crushed ice and the separated solid isolated
by filtration, washed with water and crystallized from ethanol
to give 0.18 g (49%), mp 170 C; IR (m, cm1): 3025 (aromatic
CAH), 2921 (aliph. CAH), 1684 (C4, C6 assoc.),
1H NMR
(400 MHz, CDCl3) d (ppm): 7.71–7.05 (m, 8H, ArAH), 2.32,
1.89 (s, 3H, ArACH3),
13C NMR (100 MHz, CDCl3) d
(ppm): 166.32 (C4), 164.55 (C6), 144.16 (C3), 142.83 (C5),
133.42, 132.36, 131.73, 130.92, 129.78, 129.15, 128.55, 128.22,
127.93, 126.88, 110.12 (C-3a), 23.24, 18.77 (ArACH3), MS
(m/z): Calc. = 318.1, Found = 318.1.Please cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
http://dx.doi.org/10.1016/j.jscs.2016.05.0082.2.49. 2-(2,5-Dimethylphenyl)-3-phenylpyrrolo[3,4-c]
pyrazole-4,6(2H,5H)-dione (19a)
Compound 18 of 0.159 g (0.5 mmole) was dissolved in 20 mL
ethanol and 0.019 mL (1 mmole) ammonia was added to the
reaction pot and refluxed for 48 h. The solvent was evaporated
and residue compound was washed with ether and the formed
precipitated product was filtered and the crude product was
from ethanol by crystallization (0,13 g, 75%), mp 230 C; IR
(m, cm1): 3310 (NAH), 3053–3025 (aromatic CAH), 2917
(aliph. CAH), 1661 (C4, C6),
1H NMR (400 MHz, DMSO) d
(ppm): 10.01 (s, 1H, NH), 8.07–6.42 (m, 8H, ArAH), 1.86,
1.28 (s, 3H, ArACH3),
13C NMR (100 MHz, DMSO) d
(ppm): 168.24 (C6), 165.30 (C4), 144.51 (C3), 142.14 (C5),
137.41, 135.13, 133.35, 131.41, 130.41, 129.82, 129.69, 128.55,
127.26, 125.37, 112.71 (C-3a), 23.30, 20.51 (ArACH3), MS
(m/z): Calc. = 317.1, Found = 317.1.
2.2.50. 2-(2,5-Dimethylphenyl)-5-ethyl-3-phenylpyrrolo[3,4-c]
pyrazole-4,6(2H,5H)-dione (19b)
Compound 18 of 0.159 g (0.5 mmole) was dissolved in 20 mL
ethanol and 0.045 g (1 mmole) ethyl amine was added to the
reaction pot and refluxed for 48 h. The solvent was evaporated
and residue compound was washed with ether and the formed
precipitated product was filtered and the crude product was
from ethanol by crystallization. (0,15 g, 74%), mp 230 C;
IR (m, cm1): 3000 (aromatic CAH), 2914 (aliph. CAH),
1700 (C4, C6),
1H NMR (400 MHz, CDCl3) d (ppm): 8.07–
6.43 (m, 8H, ArAH), 4.26 (q, 2H, CH2), 2,33, 1.76 (s, 3H,
ArACH3), 1.35 (t, 3H, CH3),
13C NMR (100 MHz, CDCl3)
d (ppm): 167.29 (C6), 164.35 (C4), 143.57 (C3), 141.04 (C5),
137.12, 135.30, 133.38, 131.36, 130.24, 130.09, 129.71, 129.36,
128.70, 125.81, 109.41 (C-3a), 51.32 (CH2), 20.13, 17.80
(ArACH3), 13.50 (CH3), MS (m/z): Calc. = 345.1,
Found = 345.1.
3. Results and discussion
3.1. Chemistry
4-Acyl-pyrazole-3-carboxylic acids 1a,b, which were our start-
ing compounds, were synthesized via the reaction of furan-
diones F with hydrazone (1-benzylidene-2-(2,5-dimethyl-
phenyl)-hydrazine) by heating in without any solvent media,
and its acid chlorides 2a,b were obtained absolutely. Then
these novel derivatives were converted into the corresponding
derivatives such as the ester, ureid and amide (Scheme 1). In
addition, the other pyrazole derivatives that were outlined in
the Scheme 1 were obtained with miscellaneous reactants
under mild reaction conditions. All newly synthesized com-
pounds were confirmed by spectroscopic methods which are
in agreement with our previous findings [52].
Pyrazole-3-carbonyl-urea derivatives 3 g,h,i,s,t,u were syn-
thesized by means of the reaction between acid chlorides 2a,
b and urea derivatives in the usual way [51]. Moreover, thiour-
eide derivatives 3 k,l were prepared by two chemical proce-
dures, both the reaction of the amine derivatives (NH3, Et-
NH2) with pyrazole-3-carbonyl isothiocyanate 3j and the reac-
tion of the acid chloride 2a with thiourea derivatives.
In the case of pyrazole-3-carbonyl isothiocyanate 3j, the
correct structure was established by 13C NMR spectroscopyicrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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Scheme 1 The ester, ureid and the amide derivatives of pyrazole-carboxylic acids 1a,b.
12 A. C¸etin, _I. Bildiriciin which characteristic C‚O peaks were observed at d 190,
183 ppm and N‚C‚S peak was observed at d 147 ppm.
Pyrazole ring which has functional group such as car-
bonyls, esters, carboxylic acids and nitriles in the vicinal posi-
tions is a convenient starting material for further reactions of
pyrazole to build the pyrazolo[3,4-d]pyridazine system [51].
The pyrazole acids 1a,b were cyclized with variable hydrazines
to yield pyrazolo[3,4-d]pyridazinone derivatives 4a-n
(Scheme 2). Structure elucidations of 4a-n are mainly based
upon 13C NMR spectroscopy. Signals of carbon atoms of
the pyrazolo-pyridazine rings are assigned at about 160.0
(C-7), 145.0 (C-7a), 143.0 (C-3), 140.0 (C-4) and 110.0
(C-3a) ppm.
5-Phenyl-1-(2,5-dimethyl-phenyl)-1H-pyrazole-3,4-dicarbo-
xylic acid 5 that is the main output compound was prepared
from the basic hydrolysis of 1b in high yield (85%). The struc-
ture of 5 was clarified with two carboxylic acid proton signals
at d 10.37 and d 9.88 ppm, and two carbonyl carbon signals atN
NPh
R1 O
N N
H3C
CH3
R2 NHNH2 1
a
b
R1
-Ph
-OEt
4
4 R1
a -Ph -Ph
b -Ph -H
c -Ph -Ph(CH3)2(2,5)
d -Ph -Ph(CH3)2(3,4)
e -Ph -Ph(NO)2(2,4)
f -Ph -Ph(Cl)3(2,4,6)
g -Ph -Ph(CF3)(4)
4 R1
h -OEt -Ph
i -OEt -H
j -OEt -Ph(CH3)2(2,5)
k -OEt -Ph(CH3)2(3,4)
l -OEt -Ph(NO)2(2,4)
m -OEt -Ph(Cl)3(2,4,6)
n -OEt -Ph(CF3)(4)
R2
R2 R2
N
NPh
R1 OH
O O
H3C
CH3
1
Scheme 2 Cyclization of pyrazolo[3,4-d]pyridazinone derivatives.
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http://dx.doi.org/10.1016/j.jscs.2016.05.008d 167.8 and d 164.6 ppm and the characteristic IR absorption
bands at 3392–2600 cm1 (COOH), 3058, 3022 cm1
(ArACAH), 1716, 1670 cm1 (acid, C‚O).
All ester derivatives (3a, 3b, 3m, 3n, 7a, 7b) of this study
were obtained in two different methods which are the
Schotten-Baumann and Fischer esterification. Diamide and
diureide derivatives 7c–g were obtained via reactions of 6 with
various amine and urea derivatives (Scheme 3).
The pyrazolo-carbodiamide 7e and pyrazolo-carboamide
3c, 3o derivatives were treated with a mixture of DMF and
SOCl2 at 5 C for 2 h to give pyrazolo-carbonitrile 8 deriva-
tives (Scheme 4). Characteristic 13C NMR and IR signal of the
nitrile group(s) in 8a–c are found at 107–116 ppm and 2162–
2207 cm1, respectively (see Experimental).
Regio-specific decarboxylation of 5 at high temperature
(200 C) revealed that nitrogen atom of pyrazole adjacent to
carbon atom is a driving force for decarboxylation probably
due to the hydrogen bonding between lone pair of nitrogen
and hydrogen atom of the carboxylic acid. The formation of
decarboxylated pyrazole 9c was confirmed by basic hydrolysis
of 9b followed by decarboxylation of 1b (Scheme 5) [59].
One of the most important examples for further derivatiza-
tion of 4-acyl-pyrazolo-3-carboxylic acids which includes the
reactions of corresponding pyrazolo-3-carbonyl chloride with
4-methyl-2-hydroxy-acethophenone in basic media was
reported by our research group [60]. The mechanistic details
of rearrangement reaction were displayed in our former study.
To repeat this reaction with a new pyrazole acid, 2a was
reacted with 4-methyl-2-hydroxy-acethophenone under basic
condition at room temperature. Forming of 10 was explained
with Baker–Venkataraman rearrangement in one-pot as an
instance of domino reaction [61]. Further reaction of 10
included the cyclization to obtain pyrazol-3-methyl-4H-
chromen 11 after removing H2O using H2SO4 (See Scheme 6).
On the other hand, 3,4-dibenzoyl-pyrazole 12 was synthe-
sized from two different compounds by Friedel–Crafts acyla-
tion. Refluxing of corresponding derivatives 2a and 6 in dry
benzene with AlCl3 as catalyst resulted in the formation oficrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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Synthesis and antimicrobial activity of 4-acyl-pyrazoles 1312. In continuation of the reaction, 3,4-dibenzoyl-pyrazole 12
was cyclized using anhydrous hydrazine to furnish pyrazolo
[4,3-d]pyridazine 13 (Scheme 7).
Pyrazolo-pyridazine derivatives have shown biological
activities such as antimicrobial, antiinflammatory and anal-
gesic activities [62]. Therefore, in addition to 4, we synthesized
various derivatives of pyrazolo-pyridazine 13, 14, 15 by several
different methods (Scheme 8). Reaction of 7a with anhydrous
hydrazine in dry toluene led to the formation of the 2-(2,5-di
methylphenyl)-3-phenyl-5,6-dihydro-2H-pyrazolo[4,3-d]pyridaPlease cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
http://dx.doi.org/10.1016/j.jscs.2016.05.008zine-4,7-dione 14. Structure of this compound was confirmed
with spectral data especially mass spectrum (See Experiments).
The mass spectra showed the presence of molecular ion peak
M+ at m/e 332.1. Furthermore, as a result of cyclization of
pyrazole-3,4-dicarbonitrile 8c under reflux condition of etha-
nol with anhydrous hydrazine, 4,7-diamino-pyrazolo[3,4-d]
pyridazine 15 occurred at 75% yield (Scheme 8). Structure elu-
cidation of 15 is mainly based on 13C NMR spectroscopy.
Peaks at 163.34 (C-7), 163.15 (C-4), 145.54 (C-7a) and
114.18 (C-3a) ppm are assigned to carbon atoms of the pyri-
dazine ring of 15.
Reaction of the acid 1a with excess hydroxylamine
hydrochloride under solid phase, inside an oil-bath at approx-
imately 150–155 C led to the formation of the pyrazolo[4,3-d]
oxazinone 16 (Scheme 9). Confirming of structure of 16 is
based on particularly elemental analysis and the other spectral
data (see Experimental).
Methyl groups at benzene ring were subjected to oxidize to
reach another carboxylic acid group which might give more
soluble pyrazole in water. To serve this purpose, oxidizing
reagent, Na2Cr2O7, was applied and surprisingly, it was
observed that only one methyl group was oxidized. According
to chemical shift of functional groups, we found out that orto-
substituted methyl group was only oxidized to carboxylic acid
[63]. This might be because of the facts that free lone pair of
nitrogen atom close to the ortho-methyl group serves as a
ligand for metal (Scheme 9).
As a result of dehydration of 5 in DMF/SOCl2 at 5 C,
furo[3,4-c]pyrazole-4,6-dione 18 compound was occurred at
49% yield. This compound is remarkably stable (mp 170 C)
and the structure of 18 obtained in this way was confirmed
by analytical and spectral data (see experimental). In the mass
spectra, molecular ion peak M+ appeared at m/e 318.1 (75%).
Moreover, furandione ring in compound 18 was converted
into pyrrolo[3,4-c]pyrazoledione derivatives 19 via a reaction
with ammonia and ethyl amine in ethanol. This type of hetero-
cyclic ring is not found in the literature interested in 4-acyl-
pyrazole derivatives so far. Structure elucidation of these com-
pounds were done by spectroscopic data (18 m/e: 317.1 (50%),
19 m/e: 345.1 (75%)) (Scheme 10).
3.2. Biological evaluation (antibacterial activities)
The in vitro antibacterial activities of novel synthesized com-
pounds were determined against gram-positive bacteria includ-
ing Bacillus subtilis and Staphylococcus aureus and gram-
negative bacteria including Escherichia coli, Pseudomonas
aeruginosa and Klebsiella pneumonia via using well diffusion
method (zone inhibition) [64,65]. Briefly, a bacterial suspen-
sion was added to sterile nutrient agar at 45 C and the mixtureicrobial activity of 4-acyl-pyrazoles, Journal of Saudi Chemical Society (2016),
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14 A. C¸etin, _I. Bildiriciwas poured into Petri dish on a horizontally levelled surface.
After the medium was solidified, wells of dish were made in
the agar medium. Subsequently 25 ll, 50 ll, and 100 ll of
the newly synthesized compounds suspensions were loadedN
NPh
16
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Scheme 9 Further reaction
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http://dx.doi.org/10.1016/j.jscs.2016.05.008into the wells separately. The Petri dishes were incubated at
37 C for 1 day in an oven. Experiments were carried out in
triplicate and average zone diameters were measured. Com-
pounds showing growth inhibition zones (P9 mm) were
replicated using the two fold serial dilution technique.
Erythromycin (15 mg), Rifampicin (5 mg) and Amikacin
(10 mg) antibiotics were used as positive control. Dimethylsul-
foxide was used as control and no visible inhibition zone was
observed on control groups. The solutions of all compounds
were prepared in double distilled water.
As presented in Table 1, some of the newly synthesized
compounds showed the minimal inhibitory concentrations
(MIC, lg/mL) and inhibition zone (mm) against all the
screened gram-positive bacteria and gram-negative bacteria.
It can be seen on Fig. 2 that some of the compounds 2a, 4a,
4e, 4f, 4g, 3e, 3g, 3i, 2b, 4h, 4m, 4n, 4l, 8b, 19a, 19b showed
higher activity than Amikacin against S. aureus (MIC, 25–
100 lg/mL). Compounds 2a, 2b, 4a, 4b, 4c, 4d, 4h, 4m, 4n, 6,
7f, 15, 19a, 19b displayed higher antimicrobial activities than
Rifampicin (reference drug) against the P. aeruginosa bacteria
(Fig. 3). Compounds 2a, 4a and 4l exhibited more inhibitory
activities than Amikacin against K. Pneumonia, a gram-
negative bacterium (MIC 100 lg/mL) among all compounds
tested. On the other hand, compounds 2a, 3e, 3f, 4f, 4g, 4m
and 4n exhibited more inhibitory activities than AmikacinN
NPh
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Table 1 Minimal inhibitory concentrations (MIC, lg/mL) and inhibition zone (mm) of some new synthesized compounds.
Compound No MICa in lg/mL and zone of inhibition (mm)
Bacteria
Gram-positive bacteria Gram-negative bacteria
B. subtilis S. aureus E. coli P. aeruginosa K. pneumonia
1a 100 (9) 100 (9) –b – –
2a 50 (12) 100 (11) 50 (10) 25 (10) 100 (11)
2b 50 (11) 100 (10) 100 (10) 50 (9) 50 (10)
3e 50 (13) 100 (10) 100 (10) – 50 (10)
3f 100 (12) 50 (10) 50 (10) – 50 (10)
3h 100 (10) – – – –
3i 100 (10) 100 (10) 100 (9) – 50 (9)
3j 100 (9) 100 (9) 50 (9) – –
3k 100 (9) – 100 (9) – –
3l 100 (9) – 100 (9) – –
4a 50 (10) 50 (10) 50 (9) 100 (9) 100 (11)
4b 100 (10) 50 (9) – 50 (9) 50 (9)
4c 50 (9) 50 (9) 50 (10) 50 (9) –
4d 50 (9) 50 (9) 50 (10) 50 (9) –
4e 25 (11) 50 (11) 50 (11) – –
4f 50 (14) 50 (11) 25 (10) – 50 (9)
4g 25 (13) 50 (12) 50 (10) – 50 (9)
4h 50 (10) 50 (10) 50 (9) 50 (10) 50 (9)
4m 25 (13) 50 (13) 50 (12) 50 (10) 100 (10)
4n 25 (13) 50 (12) 50 (11) 100 (9) 50 (10)
4l 50 (11) 100 (11) 50 (11) 100 (10) 100 (11)
6 100 (10) 50 (9) 100 (12) 100 (9) 50 (9)
7e 100 (10) – – – –
7f 100 (11) – – 100 (9) –
7g 100 (10) 100 (9) 50 (9) – –
8a 100 (10) – – – 100 (9)
8b 100 (9) 50 (10) – – 100 (9)
8c 100 (9) – 100 (9) – 100 (9)
9c 100 (9) – – – –
10 50 (10) 100 (9) – – –
12 50 (9) – 100 (10) – 50 (9)
15 100 (9) – 50 (10) 100 (9) –
16 100 (10) 50 (9) 50 (10) – –
17 100 (10) 100 (9) – – –
18 100 (10) – – – –
19a 100 (11) 50 (10) 50 (11) 50 (10) 50 (9)
19b 100 (11) 100 (10) 50 (11) 100 (10) 50 (9)
Ref. drugs
Erythromycin 100 (20) 100 (21) 100 (19) 100 (19) 100 (19)
Rifampicin 100 (21) 100 (18) 100 (18) 100 (8) 100 (19)
Amikacin 100 (11) 100 (9) 100 (13) 100 (14) 100 (10)
a MIC: Minimal inhibitory concentration values with SEM= 0,02.
b (–): Totally inactive (no inhibition).
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Figure 2 Antibacterial activity of against Staphylococcus aureus bacteria.
Figure 3 Antibacterial activity of against Pseudomonas aeruginosa bacteria.
16 A. C¸etin, _I. Bildiriciagainst B. subtilis, gram-positive bacteria. Also reference drugs
showed more inhibitory activities than all of the newly synthe-
sized compounds against E. coli bacteria. Additionally, Ery-
thromycin showed more inhibitory activity than all of the
newly synthesized compounds against all tested organisms.
On the other hand, compounds 2b, 3t, 4e, 4l, 19a and 19b were
equipotent to Amikacin in inhibiting the growth of B. subtilis.
Also compounds 2b, 3e, 3f, 4m and 4n were equipotent to Ami-
kacin in inhibiting the growth of K. pneumonia.
Finally, it can be suggested that these newly synthesized
compounds might have potential antibacterial activity owing
to containing pyrazole, pyridazine, oxazine and pyrrole rings.
Besides among these series, some compounds that contain
chlorine, fluorine groups at different position to the phenyl
ring showed similar activities compared to the reference drugs.
The compounds containing electron withdrawing substituents
at different position such as chlorine and fluorine showed good
activity against P. aeruginosa and S. Aureus. Our results indi-
cate that substituents containing different groups such as chlo-
rine, fluorine, methyl and NO2 are able to increase the
biological activities of compounds. In conclusion, the substi-
tuted pyrazoles showed a wide variety of biological and phar-
macological activities and might have a wide application both
in pharmaceuticals and in the agricultural industry. Therefore,
the methods developed for the synthesis of these compounds
are becoming more important.4. Conclusions
We have gathered a lot of new derivatives of 4-acyl-pyrazole in
a single work. All of our synthesized compounds have one or
two important rings and so, we think that these derivatives
may occupy a vital place in pharmaceutical fields. Besides,Please cite this article in press as: A. C¸etin, _I. Bildirici, A study on synthesis and antim
http://dx.doi.org/10.1016/j.jscs.2016.05.008according to the in vitro studies, some of our promising com-
pounds might be new candidates as new generation antibacte-
rial drugs.
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